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Background: Antiangiogenic agents have been recently added to the oncological armamentarium with bevacizumab
probably being the most popular representative in current clinical practice. The elucidation of the mode of action of
these agents is a prerequisite for personalized prediction of antiangiogenic treatment response and selection of
patients who may benefit from this kind of therapy. To this end, having used as a basis a preexisting continuous
vascular tumour growth model which addresses the targeted nature of antiangiogenic treatment, we present a
paper characterized by the following three features. First, the integration of a two-compartmental bevacizumab
specific pharmacokinetic module into the core of the aforementioned preexisting model. Second, its mathematical
modification in order to reproduce the asymptotic behaviour of tumour volume in the theoretical case of a total
destruction of tumour neovasculature. Third, the exploitation of a range of published animal datasets pertaining to
antitumour efficacy of bevacizumab on various tumour types (breast, lung, head and neck, colon).
Results: Results for both the unperturbed growth and the treatment module reveal qualitative similarities with
experimental observations establishing the biologically acceptable behaviour of the model. The dynamics of the
untreated tumour has been studied via a parameter analysis, revealing the role of each relevant input parameter to
tumour evolution. The combined effect of endogenous proangiogenic and antiangiogenic factors on the angiogenic
potential of a tumour is also studied, in order to capture the dynamics of molecular competition between the
two key-players of tumoural angiogenesis. The adopted methodology also allows accounting for the newly
recognized direct antitumour effect of the specific agent.
Conclusions: Interesting observations have been made, suggesting a potential size-dependent tumour response
to different treatment modalities and determining the relative timing of cytotoxic versus antiangiogenic agents
administration. Insight into the comparative effectiveness of different antiangiogenic treatment strategies is
revealed. The results of a series of in vivo experiments in mice bearing diverse types of tumours (breast, lung,
head and neck, colon) and treated with bevacizumab are successfully reproduced, supporting thus the validity
of the underlying model.
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Solid tumours progress through two separable phases:
the avascular and the subsequent vascular one. In the
initial phase that a tumour goes through, nutrients and
oxygen are delivered to the tumour cells via diffusion
processes alone from surrounding host capillaries. While
in this phase, the tumour can be supported to grow to a
diameter of just a few millimetres (1–2 mm) corre-
sponding to a population threshold of 106 cancer cells.
The tumour could remain at this critical size, where cell
proliferation is balanced by cell death, for a period of
several months or even years without causing any serious
damage to the host [1]. This phase is exploitable by
in vitro experimentation, where tumour cells are culti-
vated in the laboratory as three-dimensional spheroids [2].
Eventually, the tumour mass reaches the critical point
of transition from avascular to vascular phase and develops
an intrinsic blood supply network which allows it to grow
further. At this point, tumour cells secrete angiogenic fac-
tors such as vascular endothelial growth factor (VEGF) in
response to hypoxia and thus, the angiogenic activation
process termed as the angiogenic switch, occurs. Endothe-
lial cells are then triggered to secrete matrix metallopro-
teinases that facilitate cell migration and proliferation by
degrading the basement membrane. Endothelial cells will
proliferate and eventually, the tumour will be penetrated by
vessels. Finally, maturation of several vessels will occur as a
result of molecular competition between activators and
inhibitors regulating angiogenesis [3, 4].
Experimental and clinical evidence suggest that tumour
angiogenesis, i.e. the tumour-induced growth of new
capillary blood vessels in the body from already existing
vasculature, is a key process in tumour development
and cancer invasion. In particular, once angiogenesis
has obtained its goal, new vessels provide the tumour
mass with nutrients and oxygen, which are clearly of
vital importance for its survival and further growth.
Hence, the tumour may soon reach a cancer cell popu-
lation of the order of magnitude of 109, give rise to the
first symptoms [5, 6] and eventually form metastases in
distant organs. Angiogenesis occurring in a physio-
logical context, e.g. during early embryogenesis [7] as
well as in the female reproductive system [8] is com-
pletely different in numerous aspects comparing to
tumour – induced angiogenesis. The latter, does not
tend to create mature and stable vessels able to provide
normal blood supply [4, 9]. Instead, tumour vasculatureis characterized by a complex and dysfunctional struc-
ture resulting in higher fractal dimension [4, 10].
The concept of antiangiogenic treatment was originally
introduced by J. Folkman. It was based upon the idea
that the growth of a tumour is strongly dependent on the
amount of blood vessels that it induces to grow [11, 12].
However, it was not until the nineties that initial experi-
mental results suggesting that angiogenesis blockage could
result in tumour regression came up [13]. Hence, the ori-
ginal target of antiangiogenic treatment was to block the
transfer of nutrients and oxygen to the tumour by destroy-
ing the tumour vasculature until all cancer cells starve to
death. That is why it was believed that the specific kind of
treatment would be able to cure the disease. Even though
there is now enough evidence that this is not the case, sev-
eral mechanisms of action of angiogenic inhibitors have
been elucidated in order to explain their anticancer effect.
The present work focuses in simulating the antitumour
effect of bevacizumab, probably the most popular repre-
sentative of the wider family of antiangiogenic agents in
current clinical practice. In particular, bevacizumab is a re-
combinant humanized monoclonal antibody that acts by
binding to VEGF, i.e. the main mediator of tumour
angiogenesis, thereby inhibiting its interaction with the
corresponding VEGF receptors on the surface of endo-
thelial cells. Thus, with VEGF being thought to play a
central role in the formation of tumour metastases [14],
bevacizumab is considered a promising strategy for treating
metastatic sites [15]. Various studies have been sought in
order to analyse the actual efficacy of bevacizumab
treatment [16]. Bevacizumab is currently believed to
have multiple effects in tumour vasculature:
i. It induces regression of existing tumour vasculature
[17, 18],
ii. It inhibits the proliferation of endothelial cells, thus
causing impairment of further vessel growth [19],
iii. It normalizes surviving tumour vasculature
facilitating the delivery of chemotherapeutic agents
to the tumour tissue [20–22]. In particular, the
antiangiogenic treatment effect is believed to
improve both functionally and morphologically the
abnormal and chaotic structure of tumour vessels.
This transient effect, known as vascular normalization,
results in a more normal and organized vasculature
network. It is considered of vital significance since a
major issue of chemotherapy treatment is the fact that
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bypasses large areas of the tumour [23, 24], not
being able to access all target sites due to the high
abnormality of tumour vessels. Moreover, in the
recent years, the scientific community has determined
additional benefits of vascular normalization, such as
the fact that it enhances radiosensitivity and tumour
immunogenicity [25]. The latter is obtained via a
better and easier access of leukocytes into the tumour
parenchyma.
During the first years of the 21st century and up to
this point in time much progress has been made towards
developing mathematical models which describe malig-
nant tumour growth while taking into account tumour in-
duced angiogenesis explicitly [3, 26, 27], or even implicitly,
as perturbator of the proliferation related parameters that
characterize the tumour (through the modification of the
probability of a newborn cell to re-enter the cell cycle in
relation to the respective probability value in the largely
necrotic layer of the tumour) [28–30].
A modelling approach considered to be a milestone in
vascular tumour growth related literature due to its
validity and minimal parameterization is the work by
Hahnfeldt and colleagues, found in [31]. This model
describes tumour growth under angiogenic signalling
and to the best of our knowledge, it is the first model
that incorporates a variable carrying capacity accounting
for the time-dependent resources available to the tumour
system. Following this work, many similar approaches
have come up by investigating, generalizing, modifying
[26, 32, 33] and/or extending the rationale suggested by
Hahnfeldt et al. [31]. Various model extensions have been
developed on this basis so as to distinguish between differ-
ent subpopulations such as quiescent and cycling endothe-
lial cells [34] as well as mature and immature endothelial
cells [35]. Several approaches have also accounted for
combination treatment consisting of the antiangiogenic
agent in conjunction with radiotherapy [36, 37] or
chemotherapy [10]. Additionally, it has been attempted
to address chemotherapy resistance [38] as well as vas-
cular pruning [39]. Another modification that is worth
mentioning, is the one introduced by Bodnar and Forys
[40] who have studied the impact of time delays on the
model, for several versions of the initial modelling ap-
proach. Specifically, time delays were introduced in
tumour growth as well as stimulation and inhibition of
tumour vasculature. In many cases, a control theoretic
setting has been selected, aiming at identifying optimal
protocols of antiangiogenic regimens as well as com-
bination treatment schemes [10, 36, 37, 41, 42]. Finally,
Poleszczuk et al. [43], the work of whom is the basis
for our modelling approach, have claimed that the
model of Hahnfeldt et al. does not address the mode ofaction of antiangiogenic treatment acting on the signal-
ling level. Instead, it addresses antivascular treatment
effect acting cytotoxically on endothelial cells. Thus,
they have modified a term of the initial model such that
it simulates the actual mechanism of action of this kind
of targeted therapy. More details on this work are pro-
vided in the Methods section along with the mathematical
formulation of our approach.
To the best of our knowledge, the models developed
up to this point in time, do not address the following
issues. First of all, the standard bevacizumab mode of
administration to human i.e. intravenous infusion. On
the contrary, an instantaneous bolus is the standard as-
sumption made [31, 43]. Additionally, according to the
pertinent literature which is presented in the respective
subsection, the one-compartment pharmacokinetic model
which is the standard assumption in the existing models
appears to be inferior to the more refined two-
compartmental models that best describe bevacizumab
pharmacokinetic properties. Pharmacokinetic constant
values for an infusion two-compartmental bevacizumab
pharmacokinetic model reported in literature, have
been utilized. Secondly, the existing models do not ap-
pear to mathematically reproduce the asymptotic be-
haviour of a tumour volume in the theoretical case of
total destruction of tumour neovasculature. Finally, to the
best of our knowledge, the range of tumour types ad-
dressed by antiangiogenic models up to now has been very
limited [44]. In order to broaden the range of tumour
types addressed by the existing models for experimental
fitting purposes we have exploited experimental data from
four different tumour types (breast, lung, colon, head and
neck).
The long term aim of our approach is to develop a
specific Oncosimulator [45] based on a clinically adapted
and validated multiscale model of vascular tumour growth
and response to treatment. Certain models that have ap-
peared in literature rely on preliminary validation based
mostly on logical and mathematical tests and gross quali-
tative observations of experimental and/or clinical reality.
Some other models, including the present work as well as
previous work of our group [28, 46], also attempt a quanti-
tative fitting to sets of experimental and clinical data
[31, 44, 47]. Motivation to develop the present model has
been provided by the large-scale European Commission
funded project p-Medicine. Within the framework of this
project, Oncosimulators [45] for the optimal personalized
treatment of breast cancer patients treated with bevacizu-
mab had to be developed.
The structure of the paper is the following: The
Methods section consists of five subsections. Firstly, the
continuous vascular tumour growth model stemming
from the work in Poleszczuk et al. [43] is presented.
Relevant equations are explained and model parameters
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of bevacizumab pharmacokinetics are provided. Next,
we elaborate on the numerical solution and implementa-
tion of the model and we demonstrate in a graphical
way the information flow within the vascular tumour
growth model under bevacizumab monotherapy model
as a whole. The fourth subsection deals with the method-
ology of the conducted parameter analysis. Finally, there is
one last subsection, outlining the methodology adopted
for the fitting process. The Results and Discussion section
includes three subsections. First, specific results revealing
both free growth and tumour growth under bevacizumab
monotherapy pattern are presented. Second, the param-
eter analysis results are shown, revealing the effect of
model parameters involved on the dynamics of the bio-
logical system. Third, the results of the conducted fitting
process are presented and discussed. Finally, conclusions
are drawn.Methods
An early version of the vascular tumour growth model
has already been outlined in [48]. A more analytical de-
scription, along with further results, parameter analysis
and fitting of the model to actual experimental data will
be presented in the following sections.
A continuous approach to modelling the mechanism of
action of antiangiogenic treatment applied on a
vascularized tumour
The scientific problem addressed consists of three
interdependent processes: tumour development, tumour
angiogenesis and the antiangiogenic treatment effect.
Thus, a mechanistic model monitoring both the tumour
and vascular compartment while addressing the targeted
nature of the specific kind of treatment could give valuable
insight into antiangiogenic treatment mode of action. To
the best of our knowledge, the first modelling approach
meeting these requirements is the approach of [43], stem-
ming from previous, much investigated work of [31]. We
have used this approach as a basis in order to simulate
the bevacizumab monotherapy effect and reproduce the
results of a series of in vivo experiments in mice bearing
diverse types of tumours (breast, lung, head and neck,
colon).
Multiple biologically essential phenomena of cancer cell
population dynamics are incorporated into the model:
cancer cell proliferation and cancer cell death (through
the assumption of Gompertzian growth), post-vascular
dormancy (the state where tumour growth ceases due to a
balance eventually achieved between proangiogenic and
antiangiogenic factors), secretion of endogenous proangio-
genic factors (such as VEGF, fibroblast growth factors,
platelet-derived growth factor, angiopoietin-1 etc.) by thetumour, secretion of endogenous antiangiogenic factors
(such as thrombospondin, angiostatin, endostatin,
angiopoietin-2, etc.) by the tumour and natural endo-
thelial cell loss. Finally, the model takes into account
antiangiogenic treatment - induced endothelial cell death
as well as resulting tumour cell death.
To this point it should be mentioned that strictly
speaking, the model concerns monoclonal tumourigenesis.
In particular, due to the ordinary differential equations
(ODE) formalism which is valid only for homogeneous
systems, the tumour could be theoretically viewed as con-
sisting of a hypothetical clone with the average properties
of all tumour cells in space. This approximation is jus-
tifiable, as in the vascular phase in which the model is
applicable, the number of cells is big enough for the
system to be viewed as homogeneous. For the same rea-
son, the behaviour of the cancer cells can be considered
deterministic.
The dynamical system described in [43] is governed by
a pair of ODEs which reflect the interplay between
tumour volume (V) and carrying capacity (K). Before we
proceed to present the equations involved in the vascu-
lar tumour growth model, the primary assumptions on
which the model rests need to be formulated:
i. The tumour has spherical symmetry,
ii. The diffusion process via which the aforementioned
factors are transported is in a quasi-stationary state,
iii. The concentration of the stimulator is a radially
symmetric, continuously differentiable function,
iv. The clearance rate of proangiogenic factors is a
monotonically increasing function of drug
concentration and it is always greater than the
respective value in the absence of treatment,
v. The change of drug concentration inside the tumour
caused by the dysfunctional vasculature is governed
by the proportionality to a bounded and decreasing
function of tumour volume.
For the sake of completeness, a few remarks regarding
the mathematical formulation of Hahnfeldt et al. model
should be mentioned as this was the starting point and
the basis for a constantly expanding family of vascular
tumour growth models, including both [43] and the
work presented in this article. As it was also mentioned
in the previous section, the model of Hahnfeldt et al.
assumed Gompertzian growth of tumour volume V(t)
without however following the classical approach. In-
stead, they have introduced a time-dependent carrying
capacity K(t) and a dependence of the rate of change of
K (dK/dt) on K,V, and t.
The initial basis on which Hahnfeldt et al. [31] set up
the equation describing the rate of change of carrying
capacity was the one formulated below:
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of functional vasculature)+ (stimulatory capacity of the
tumour) + (endogenous inhibition of existing vasculature)
+ (impairing of tumour vasculature due to administered
angiogenic inhibitors).
The first term reflecting the intrinsic loss rate was as-
sumed to be proportional to carrying capacity, while the
last one was taken to be a typical treatment-induced
death term proportional both to carrying capacity and
drug concentration. The second and third terms, reflecting
stimulatory and inhibitory action induced by tumour cells
respectively, were computed by applying a diffusion-
consumption equation for the concentration of stimulators
and inhibitors. Assuming that the tumour is in quasi-steady
state and radial symmetry as well, the partial differential
equation (PDE) was reduced to an ODE with the stimula-
tor/inhibitor concentration as the unknown function of the
distance from the center of the tumour. Subsequently,
Hahnfeldt et al. approximated the solution for sufficiently
small clearance rate (inhibitor case) and sufficiently large
clearance rate (stimulator case), concluding that the inhibi-
tor term should tend to grow at a rate Kα ⋅Vβ faster than
the stimulator term, where α + β ≈ 2/3. Finally, following
thorough fitting of the model to experimental data, they
concluded that the term reflecting spontaneous loss of
functional vasculature is negligible.
In 2011, Poleszczuk et al. [43] have omitted the term
of Hahnfeldt et al. that reflected angiogenic inhibition
due to administered inhibitors, claiming that it actually
reflected antivascular treatment acting cytotoxically on
endothelial cells. Instead, they have modified the term
describing the endogenous angiogenic stimulatory cap-
acity of the tumour accordingly, so as to account for the
antiangiogenic treatment effect that acts on the signal-
ling level by moderating endogenous angiogenesis stimu-
lation of the tumour. In particular, they have reapplied
the diffusion-consumption equation for the concentration
of stimulators by perturbing the clearance rate by a func-
tion of antiangiogenic drug concentration. Hence, they
have mathematically formulated the dependence of the ex-
tent of angiogenic stimulation and thus the dependence of
tumour volume on the amount of drug in the host.
Following this modification, the model of Poleszczuk
et al. [43] reads:
dV
dt
¼ −λ1⋅V ⋅ ln VK
 
ð1Þ
dK
dt
¼ −λ2⋅K þ c⋅ βþ V
pð Þ⋅V
α⋅ βþ Vpð Þ þ I tð Þ−d⋅K ⋅V
2=3 ð2Þ
where V stands for tumour volume, K for carrying
capacity, I(t) for the antiangiogenic drug concentration
and λ1, λ2, c, d, β, α and p, for parameters explained in
Table 1. All coefficients are non-negative, except forproportionality constant c where only positive values
are allowed in order to preclude the biologically irrelevant
behaviour of an untreated tumour with self-regressing
carrying capacity.
Prompted by a remark made by Dr. Leonid Hanin in
his capacity as a reviewer of the present manuscript, we
have proceeded to a correction of the asymptotic behaviour
of the system as the drug concentration tends to infinity
(I(t)→∞). According to our initial gross assumption and in
agreement with the asymptotic behaviour of the ODE
model developed by [43], the tumour volume tends to zero
as I(t)→∞. This appears to be acceptable as a first approxi-
mation. However, we have adopted Hanin’s suggestion to
take into account the refined mathematical observation that
as I(t)→∞ the tumour volume should tend to V*, with V*
corresponding to the critical avascular tumour volume
which is reached when the angiogenic switch occurs.
More specifically, based on the widely acknowledged
mechanism of action of antiangiogenic agents, the ex-
pected behaviour of the system as the drug concentra-
tion tends to infinity (I(t)→∞) would be to tend to a
state (V*, K*) where V* as above and K*, represents the
carrying capacity corresponding to the tumour while in
the avascular phase. Note that K* = V* since carrying
capacity is defined as the maximal tumour volume that
can be sustained using the current resources.
However, when the antiangiogenic drug concentration
is sufficiently high (I(t)→∞) the dynamical system takes
the following form:
dV
dt
¼ −λ1⋅V ⋅ ln VK
 
ð3Þ
dK
dt
¼ −λ2⋅K−d⋅K ⋅V 2=3 ð4Þ
According to Eq. (4) the carrying capacity has become
a decreasing function, eventually turning the tumour
volume into a decreasing function as well. This will fi-
nally drive the whole system to state (0, 0).
To address this apparent discrepancy we have substituted
(V, K) for (V-V*, K-V*) preserving the structure of the
model as it was such that (V-V*, K-V*)→ (0, 0) and finally,
(V, K)→ (V*, V*). Of course, this intervention slightly
modifies the underlying assumptions as well. Specifically,
the updated equations suggest that the total amount of
tumour-induced angiogenic stimulators does not actually
depend on the entire tumour volume V but instead, on
the part of tumour volume that has been developed fol-
lowing the angiogenic switch i.e. on the quantity V-V*.
This is biologically plausible, if one takes into account that
the angiogenic switch, when the tumour has already
reached the critical size V*, is actually the moment at
which the tumour begins to overexpress angiogenic stimu-
lators [49]. In other words, once in the vascular phase
Table 1 Description of the variables and parameters used in the vascular tumour growth and the two-compartmental pharmacokinetic
bevacizumab models
Mathematical Symbol Description Units Valuea Referencea
Vascular tumour growth model
t Time day n/a -
V Tumour volume mm3 n/a -
K Tumour carrying capacity mm3 n/a -
λ1 Gompertzian growth constant day−1 0.192 [31, 43]
λ2 Proportionality constant related to the natural mortality of
endothelial cells
day−1 0 [31, 43]
c Proportionality constant related to the term reflecting endogenous
stimulation of the tumour upon the vasculature
mg/(day · mm3p · kg) 5.85 [31, 43]
d Proportionality constant related to the term reflecting endogenous
inhibition of tumour vasculature
day−1 · mm−2 0.00873 [31]
α Parameter reflecting the stimulator clearance rate mg/(mm3p · kg) 1 [43]
β Parameter reflecting the extent of the abnormal phenotype of
tumour vasculature
mm3p 1 [43]
p Parameter reflecting the extent of the abnormal phenotype of
tumour vasculature
- 0 [43]
I Drug concentration in plasma mg/kg n/a -
Two-compartmental pharmacokinetic bevacizumab model
t Time-point day n/a -
I Bevacizumab concentration in plasma mg/ml n/a -
n Number of infusions to be administered - 9 [60]
D Dose mg dosage*weight -
T Infusion duration day 1/48 [66]
Vc Volume of central compartment ml 7.975 [64]
k12 Transfer constant from central to peripheral compartment day
−1 0.7536 [64]
k21 Transfer constant from peripheral to central compartment day
−1 0.3144 [64]
ke Rate of elimination day
−1 0.3888 [64]
d Dosage mg/kg 5 [60, 61, 65]
w Host’s weight kg 0.025 [60, 64]
tD Administration time-point of anti-angiogenic treatment day t1 = 1 -
t2 = 4
t3 = 8
t4 = 11
t5 = 15
t6 = 18
t7 = 22
t8 = 25
t9 = 29
aUsed for indicative free growth and/or Intermittent bevacizumab monotherapy simulations
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tumour volume developed prior to the triggering of the
angiogenic switch does not contribute to the secretion of
proangiogenic factors and subsequently to the growth of
carrying capacity. Similarly, angiogenic inhibitors are as-
sumed depend on the quantities V-V* and K-V*.
Hence, we have:d V−V ð Þ
dt
¼ −λ1⋅ V−V ð Þ⋅ ln V−V

K−V 
 
d K−V ð Þ
dt
¼ −λ2⋅ K−V ð Þ þ c⋅ βþ V−V
ð Þpð Þ⋅ V−V ð Þ
α⋅ βþ V−V ð Þpð Þ þ I tð Þ
−d⋅ K−V ð Þ⋅ V−V ð Þ2=3
Finally, we concluded to the following ODE system
monitoring the rate of change of both the total tumour
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the total carrying capacity (i.e. adjacent and tumour-
induced),
dV
dt
¼ −λ1⋅ V−V ð Þ⋅ ln V−V

K−V 
 
ð5Þ
dK
dt
¼ −λ2⋅ K−V ð Þ þ c⋅ βþ V−V
ð Þpð Þ⋅ V−V ð Þ
α⋅ βþ V−V ð Þpð Þ þ I tð Þ
−d⋅ K−V ð Þ⋅ V−V ð Þ2 3=
ð6Þ
For the case of untreated growth where I(t) = 0 the dy-
namical system becomes:
dV
dt
¼ −λ1⋅ V−V ð Þ⋅ ln V−V

K−V 
 
ð7Þ
dK
dt
¼ −λ2⋅ K−V ð Þ þ c
α
⋅ V−V ð Þ−d⋅ K−V ð Þ⋅ V−V ð Þ2 3=
ð8Þ
Note that for the rest of this article, as in both [31]
and [43], we will omit the first term of eqs. (6) and (8),
reflecting the spontaneous loss of functional vasculature.
ODE system consisted of eqs. (7) and (8), captures the
well acknowledged tumour growth slowdown to a plat-
eau size, the value of which is determined by the even-
tual balance between angiogenic stimulators and
inhibitors. In particular, the steady state solution of the
system is:
VSS ¼ V  þ c
α⋅d
 3=2
ð9Þ
suggesting that only parameters involved in stimulator
and inhibitor term modulate the plateau value of tumour
volume.Fig. 1 Schematic representation of the two – compartmental pharmacokin
route of administration (intravenous infusion); Vc, volume of central compa
distribution rate constant from central compartment to outer compartmen
compartment; ke, elimination rate constantRegarding the value assigned to the threshold of avascu-
lar tumour volume V* throughout this work, we have
considered a threshold of tumour diameter equal to
1 mm. Indeed, relevant literature suggests that avascular
tumours in humans are limited by a maximal size of
1–2 mm of diameter [50, 51] and presents biological
evidence that avascular tumours of mice do not grow
beyond 1 mm of diameter [52]. Assuming spheroid
shape, this limit size corresponds to a tumour volume
equal to 0.52 mm3. Finally, in accordance with [43], it
is imposed that parameter α is fixed to a value of one
(mg/(mm3p · kg)) throughout this work. In the future,
further investigation on the role of parameter α is
needed as it could enable the simulation of different
tumours with common untreated growth timecourse
and diverse responses to antiangiogenic treatment.
This feature could serve as a vehicle to addressing
mechanisms like intrinsic tumour resistance to antian-
giogenic treatment [53].Inclusion of bevacizumab pharmacokinetic properties
This section outlines the computation of bevacizumab
concentration I(t) at a given timepoint t. This function is
involved in the right-hand side of Eq. (6) and more
specifically, in the term reflecting the angiogenic
stimulatory capacity of the tumour.
Regarding the pharmacokinetic properties of bevaci-
zumab, a large scale review of pertinent literature has
been conducted. Two-compartmental models assuming
first-order elimination appear to give the best description
of bevacizumab pharmacokinetic data [54–56]. Hence,
we proceeded with the implementation of a two-
compartmental pharmacokinetic model (Fig. 1). Taking
into account that the specific antiangiogenic agent is
administered to human patients via the intravenous
route, the case of intravenous infusion has been addressedetic model. ka absorption rate constant for the case of intravenous
rtment; Vout, volume of distribution of outer compartment; k12,
t; k21, distribution rate constant from outer compartment to central
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delivery into the patient’s systemic circulation.
The central compartment represents blood and all
highly perfused tissues, i.e. vital organs that are in rapid
equilibrium with blood such as lungs, kidney and liver.
Drug elimination is assumed to occur from the central
compartment according to the first order transfer rate ke
since kidney and liver are the two most important clearing
organs. The outer compartment corresponds to poorly
perfused tissues.
Given the fact that monitoring drug concentration at
the anatomical region of interest is not feasible, the
concentration of drug in plasma is typically assumed to
reflect the concentration in the site of the target tissue.
Hence, the equation characterizing the central com-
partment is the one to be introduced in the vascular
tumour growth model.
Thus, if T stands for duration of infusion, D for adminis-
tered dose and tD for timepoint of drug administration,
the function that describes bevacizumab concentration I(t)
at a given timepoint t in plasma following a single drug
infusion, is mathematically formulated as below:
While the infusion takes place, i.e. while t − tD ≤ T:
I tð Þ ¼ D
T
⋅
A
a
1−e−a t−tDð Þ
 
þ B
b
1−e−b t−tDð Þ
  
ð10Þ
During the post-infusion period, namely while T < t − tD:
I tð Þ ¼ D
T
⋅
A
a
1−e−aT
 	
⋅e−a t−tD−Tð Þ þ B
b
1−e−bT
 	
⋅e−b t−tD−Tð Þ
 
ð11Þ
where,
a ¼ k21⋅ke
b
ð12Þ
b ¼ 0:5 k12 þ k21 þ ke−
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
k12 þ k21 þ keð Þ2
q
−4k21⋅ke
 
ð13Þ
A ¼ 1
Vc
a−k21
a−b
ð14Þ
B ¼ 1
Vc
b−k21
b−a
ð15Þ
Further information on the model assumptions and
governing equations can be found in [57]. In order to
compute the pharmacokinetic effect of multiple drug
doses, all drug concentration curves are internally (in
the code) super-positioned at each simulation timepoint
so as to sum the contribution of current drug dose with
the one of previous administrations. Parameters and var-
iables involved in the pharmacokinetic model are ex-
plained in Table 1.In order to comply with the necessary uniformity of units
and given that the drug concentration is monitored in
plasma, we have internally divided the output of the imple-
mented two-compartmental model (in units of mg/ml) by
the typical value of blood plasma density (in kg/ml) [58].
Implementation and numerical solution
We proceeded with the implementation of the model in
MATLAB. The details concerning the principle m-files
are listed and explained below.
Function drug concentration
This function implements the two-compartmental phar-
macokinetic model for administration via intravenous
infusion (as is the case for bevacizumab use in clinical
practice). It calculates the concentration of the antiangio-
genic agent at each timepoint also taking into account the
contribution of all previous infusions.
Function vascular tumour growth
This function computes the derivatives involved in Eqs.
(5)-(6), which describe vascular tumour growth.
Script vascular tumour growth_main
Given the.csv file containing the parameter values, the
specific script file resolves the problem with the solver
ode45 which implements a Runge Kutta method with a
variable time step for efficient computation. It also plots
simultaneously the variables V and K (representing tumour
volume and carrying capacity, respectively) as functions
of time.
It is worth noting that the experiments concerning
free tumour growth as well as tumour growth under
intermittent bevacizumab treatment have been performed
on a desktop computer with an AMD Phenom(tm) II X6
1055 T Processor 2.80 GHz, 8.00GB RAM in Windows 7
with 64-bit operating system and that the code execution
time is of the order of a few seconds. Figure 2 demon-
strates the information flow inside the vascular tumour
growth model.
An initial step towards investigating the impact of input
parameters to the model output, for an untreated
vascularized tumour
An initial exploratory set of parametric simulations has
been conducted in order to investigate the impact of the
input factors on the output of the model as well as to
identify the model parameters exerting the greatest in-
fluence on the model predictions. This has been a two-
stage process: initially, a varying one parameter at a time
approach has been selected so as to study the dynamic
behaviour of an untreated solid tumour. The effect of
perturbing each free growth -related factor on the output
of the model when all other parameters are kept constant
Fig. 2 Information flow inside the vascular tumour growth under antiangiogenic treatment model. Parameters are explained in Table 1
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gain insight into the role of each input parameter to un-
treated tumour evolution. Although perturbations of the
reference value by diverse percentages have been applied
(±5 %, ±10 %, ±20 %, ±50 %), the results that came up ap-
plying a perturbation percentage equal to 20 % are indica-
tively presented. The impact of the input parameters has
been measured as reflected by their effect on the value of
the plateau reached by the tumour (in mm3), as well as
the timing of its attainment (in days). As a second step,
the sensitivity of the parameters that drive the angiogenic
control of the tumour has been studied with respect to the
attained value of tumour volume plateau. Their combined
effect on the plateau values is visualized in three-
dimensional space. The input parameters to be varied
are λ1, c and d.
For the needs of parameter analysis, the following is
considered:
i. The tumour has reached the plateau when the
whole number part of the value of tumour volumecoincides with the respective one of carrying capacity
for at least ten consecutive simulation time-steps.
ii. The timepoint that corresponds to the first of the
aforementioned time steps is the exact time of plateau
and the repeated value is the value of the plateau.
The aforementioned endpoints reflect the dynamics of
the untreated disease. Were the parameter investigation
conducted in the context of the therapy module, extra
endpoints should also be selected, i.e. endpoints inter-
pretable as efficacy measures of the administered antian-
giogenic treatment, such as tumour growth inhibition or
tumour volume reduction.
Reproducing the outcome of a series of in vivo
experiments in mice treated with bevacizumab
Given the fact that the effects of bevacizumab mono-
therapy were not found to be significantly dependent on
whether the drug is intravenously or intraperitoneally
administered [59], we proceed with the reproduction
of the results of a series of in vivo experiments in mice
Argyri et al. Biology Direct  (2016) 11:12 Page 10 of 31intraperitoneally treated with bevacizumab. In particular,
eight in vivo experiments conducted in mice bearing
breast (KPL-4 cell line), lung (H226 cell line), head and
neck (SCC1 cell line) as well as colon (HCT116, HT29,
HCP40 and HP40 cell lines) tumour xenografts have been
selected from relevant literature [60–62] in order to fit the
model to actual experimental data. These experiments
aimed at examining the antitumour activity of bevacizu-
mab monotherapy and combination treatment. Of course,
in the latter case, datasets corresponding to unperturbed
tumour growth and bevacizumab monotherapy arm alone
were exploitable by the model.
For the needs of fitting the model to the available data,
two extra m-files have been implemented. In particular,
a cost function has been defined as the difference be-
tween the model prediction and the actual value of the
tumour volume, for the available instances of experi-
mental data. The goal of the fitting process is to
minimize the objective function, in order to obtain the
most accurate estimation of the variables under study. A
second function has been implemented so as to specify
the parameter values that minimize the squared value of
the objective function of each data-point. We have used
Μatlab built-in function for solving nonlinear least-
squares (lsqnonlin), in conjunction with the trust region
reflective algorithm.
In order to quantify the experimental data obtained
through relevant literature [60–62], we have utilized Plot-
Digitizer software which allows data extraction (mean
value ± standard deviation) via its digitization. Assuming
that the effect of bevacizumab administration would per-
turb the parameter values that yield the simulation of the
untreated dataset, or at least some of them, the fitting
process for each experimental dataset (control group and
treatment group) has been conducted in two steps: for
each experiment, firstly, fitting of the free growth module
to the control group data and subsequently, based on the
result of the previous parameter estimation, fitting of the
respective bevacizumab monotherapy module to the
treatment group data. In cases where multiple treatment
groups were included in the same experiment (i.e. in ex-
periments 3 and 4 where there exists one treatment group
per administered dose level), the fitting of bevacizumab
monotherapy module to the treatment group data for a
specific dose level was initiated based on the result of the
parameter estimation corresponding to the nearest lower
dose level treatment group. Next, the adopted method-
ology is outlined.Fitting the free growth module Local fitting has been
performed with respect to four parameters involved in
the unperturbed vascular tumour growth module (λ1, c,
d, K0), with K0 representing the initial carrying capacity.Initial point
The least squares solver requires a user-supplied initial
point (λ1
in, cin, din, K0
in) to start from. The values of the
first three components are set in accordance with [31].
The value of parameter K0
in is selected such that for each
dataset the ratio (V0/K0
in) is equal to the corresponding
ratio in [31], where V0 is set equal to the value of the
first available experimental measurement of tumour vol-
ume for the specific dataset. This choice allows us to
mimic a realistic tumour dynamics for mice in accordance
with relevant literature.Imposed bound constraints
These specify the region of parameter space where the
least squares solver will search for the locally (i.e. around
the selected initial point) optimal solution. The value of
the first available experimental measurement of tumour
volume for each dataset has been assigned to the lower
boundary of parameter K0. This choice prevents the solver
from selecting an optimal parameter value that would yield
a biologically irrelevant behaviour such as an unperturbed
tumour growth timecourse with an initial decreasing
section. For the lower boundaries of the rest of parameters
involved in the fitting process non-negativity has been
imposed.Fitting the bevacizumab monotherapy module Local
fitting has been performed with respect to five parameters
involved in the vascular tumour growth under bevacizumab
monotherapy module, namely (λ1, c, β, p, K0). Among
those, β and p are the ones that are exclusively involved in
the therapy-related module, reflecting the pathological
structure of tumour vessel network and decreasing the drug
concentration that actually accesses the tumour. Parame-
ters λ1 and c, were selected based on the expected impact
of treatment administration on the bioprocess that each
one reflects. Thus, taking into account the mode of action
of bevacizumab binding VEGF, parameter c (involved in the
term representing endogenous stimulation of the tumour
upon the vasculature) has been allowed to fluctuate. More-
over, by also allowing the decrease of λ1 which is the unique
parameter that can affect tumour growth rate independ-
ently of the angiogenic compartment, the direct antitumour
effect that anti-VEGF therapy may induce [63] is reflected.
Given the fact that instantaneous treatment effect has been
assumed as a first approximation, K0 is allowed to fluctuate
for datasets where the first available experimental timepoint
coincides with the first administration timepoint. Parameter
d, reflecting the action of endogenous angiogenesis inhibi-
tors, is considered independent of the bevacizumab mono-
therapy effect and as such, it remains fixed to the value that
has been determined through the respective fitting of the
unperturbed growth model. Values of parameters involved
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have been extracted from [64].
Initial point
As mentioned above, the least squares solver requires a
user-supplied initial point (λ1
in, cin, βin, pin, K0
in) from
which the search of the parameter space initiates. The
values of λ1
in, and cin are the optimal values that were
determined via the previous fitting process of the cor-
responding experiment. Parameter values βin and pin
are adopted from [43]. Lacking any precise information,
the initial value K0
in, is calculated such that for each
dataset the ratio (V0/K0
in) is equal to the corresponding
ratio that has been determined in the case of the con-
trol group, where V0 is set equal to the value of the first
available experimental measurement of tumour volume
for the treatment arm dataset. However, in several datasets,
manual tuning of initial parameter values was necessary in
order to achieve a better fitting result.
Imposed bound constraints
The upper boundary of λ1, i.e. the parameter that directly
influences the tumour growth rate, has been set equal to
the respective estimated value that was determined via the
fitting of the free growth module in order to account for a
potential direct antitumour effect of bevacizumab. For the
rest of the parameters involved in the fitting process of the
treatment module, non-negativity has been imposed.
Results and discussion
Indicative tumour growth patterns
In order to study the qualitative behaviour of the model,
numerous sets of code executions have been conducted0 10 20 30
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Fig. 3 The free growth pattern. Simulation results for an untreated tumourby testing the code with different parameter values,
simulation time span, initial values and code module
(free growth, constant treatment, intermittent treatment).
Having adopted the classical graph representation, the
following indicative results are presented so as to illus-
trate several points of interest concerning the dynamics
of the model.
We have focused on the case of host-mouse due to
the availability of reference values [31, 43] as well as
the existence of relevant experimental data extracted
from literature [60–62].
Free growth
Figure 3 demonstrates the timecourse of tumour volume
and carrying capacity for the free growth of the tumour
characterized by the parameter values used by Hahnfeldt
et al. [31]. Assuming spheroid shape, timepoint 0 corre-
sponds to a tumour radius equal to 3.63 mm and thus,
to a vascularized tumour. Growth slowdown is obvious
and the asymptotic limit obtained is approximately equal
to 17347 mm3, a value consistent with the one that
comes up through the steady state solution (see Eq. (9))
as well as the results in [31]. This plateau is a theoretical
concept, representing the upper horizontal asymptote
that bounds the tumour volume never to be actually
exceeded as the tumour burden would have already
become lethal to the host [6].
Tumour growth under bevacizumab monotherapy
In order to demonstrate the qualitative behaviour of the
treatment module (Figs. 4 and 5), we proceeded with
simulating the effect of the application of a bevacizumab
monotherapy treatment scheme to a mouse weighing40 50 60 70 80
e (days)
 
tumour volume V(t)
carrying capacity K(t)
characterized by the parameter values shown in Table 1
Fig. 4 The growth pattern for a treated tumour and bevacizumab concentration timecourse in host’s plasma. a Simulation results for a tumour
treated with bevacizumab. The regimen applied has been used in the context of various in vivo experiments in mice [60, 61, 65]. Parameter
values are shown in Table 1. b The timecourse of bevacizumab concentration in plasma for the simulated treatment scheme, the details of which
are shown in Table 1. Values of parameters involved in the pharmacokinetic model for the case of host-mouse were extracted from [64]
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extracted from [43], except for parameter d which was
assigned to the value used in [31]. The simulated scheme
consists of the administration of 5 mg/kg of bevacizumab
as a single-agent, twice weekly, for a total of 9 doses. The
specific treatment scheme details i.e. dosage, number and
time interval between infusions, have been used in the
context of various in vivo experiments in mice [60, 61, 65].
Parameter values involved in the two-compartmental
pharmacokinetic model have been adopted from [64] and
are also only applicable for the case of host-mouse. Re-
garding the duration of infusion, we have considered
infusions lasting 30 minutes, i.e. the minimum value of
the typical range of the standard bevacizumab infusion
rate for human patients [66], due to the lack of relevant
mice-specific information.
Treatment begins on the 1st day, when the tumour
size has already grown to a volume equal to 269 mm3Fig. 5 Free growth pattern versus treated tumour growth pattern. a Simula
scheme used in the context of various in vivo experiments in mice [60, 61,
extended simulation time duration (150 days). b The time course of bevaci
the details of which are shown in Table 1. Values of parameters involve
extracted from [64]i.e. when the tumour radius of is approximately equal to
4 mm assuming spheroid shape. Taking into account
that timepoint 0 corresponds to a tumour of 200 mm3,
it can be observed that an initial overshoot of tumour
volume (V) occurs, due to the fact that the tumour has
been so far untreated. With the start of the regimen
administration, a sharp decrease of carrying capacity is
obvious as well as the subsequent response of tumour
volume. This pattern reflects the fact that antiangiogenic
treatment targets directly the vascular compartment and
through that, the tumour compartment responds. How-
ever, it is worth noting that the specific tumour is not re-
sponsive in terms of treatment-induced tumour shrinkage
but only in terms of tumour growth inhibition, i.e. com-
paring to the tumour evolution in the case of untreated
growth (Fig. 5a). A closer inspection of Fig. 4a, reveals that
each time the curve K(t) intersects curve V(t), the mono-
tonicity of function V(t) alters. This behaviour that can betion results for a tumour treated with bevacizumab according to a
65] and characterized by the parameter values shown in Table 1 for an
zumab concentration in plasma for the simulated treatment scheme,
d in the pharmacokinetic model for the case of host-mouse were
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capacity is actually defined as the maximal tumour volume
that the current vascular system can support. Figure 4b
shows the time evolution of bevacizumab concentration in
plasma as computed via the two-compartmental pharma-
cokinetic model.
Extending simulation time enables the study of the
treatment impact on the attainment of the upper limit
that constitutes the plateau of the tumour, namely, it
allows the study of the treatment effect in its entirety.
Hence, the numerical simulation has been extended to
a simulation time period equal to 150 days. The
respective results suggest that the treatment adminis-
tration has not affected the value of the plateau, yet it
has caused a considerable growth delay of 85 days
(Fig. 5a).
The behaviour demonstrated in Fig. 5a provides clear
indications of the temporary effect of antiangiogenic
treatment, being however able to delay tumour evolution.
In particular, a tumour growth inhibition by 19.38 % can
be observed, computed as the percentage of change in
tumour volume in the treatment module simulation with
respect to the free growth module simulation, at the end
of the treatment (i.e. day 32).Fig. 6 The effect of perturbing parameters λ1, c and d on the volume of th
value [31] when all other parameters are kept constant at the reference value
around its reference value [31] when all other parameters are kept constant a
reference value [31], when all other parameters are kept constant at the refereParameter analysis results
Perturbing parameter λ1 Equation (7) shows that the
Gompertzian growth constant λ1 is the only parameter
that affects tumour growth rate independently of the an-
giogenic compartment, making it thus a direct modula-
tor of the doubling time characterizing the simulated
tumour at each timepoint. All parameters have been
kept constant, while λ1 has been perturbed by a uniform
20 per cent either side of the reference value (Fig. 6a)
which has been set equal to 0.192 day−1 [31]. Hence,
values 0.192 day−1, 0.2304 day−1 and 0.1536 day−1 have
been assigned to λ1. Taking Eq. (7) into account, it is ex-
pected that for untreated disease, higher values of λ1
would result in a more aggressive tumour. Indeed, as
demonstrated in Fig. 6a, increasing the value of λ1 leads
to a faster growing tumour, while decreasing the value of
λ1 has the opposite effect. From the viewpoint of the se-
lected endpoints, a closer inspection of Fig. 6a reveals
the impact of parameter λ1 to the actual timepoint that
the tumour attains the plateau. On the contrary, as it is
also expected based on Eq. (9), the specific parameter
does not affect the value of the plateau. The measured
effect is presented in Table 2.e untreated tumour. a. λ1 is perturbed by ±20 % around its reference
s [31] on the volume of the untreated tumour. b. c is perturbed by ±20 %
t the reference values [31] and c. d is perturbed by ±20 % around its
nce values adopted in [31]
Table 2 Effect of the variation of one input parameter value at a time, on the value of the tumour plateau as well as on the
timepoint of its attainment
Parameter values Units Time of plateau (day) Value of plateau (mm3) Variation of plateau value (%)
λ1 Reference value 0.192 day
−1 95 17347 n/a
+20 % 0.2304 79 17347 0
−20 % 0.1536 118 17347 0
c Reference value 5.85 day−1 95 17347 n/a
+20 % 7.02 96 22803 +31.45 %
−20 % 4.68 101 12413 −28.44 %
d Reference value 0.00873 day−1 · mm−2 95 17347 n/a
+20 % 0.010476 87 13196 −23.93 %
−20 % 0.006984 99 24243 +39.75 %
All results regarding variation of plateau value are in agreement with the respective calculations based on Eq. (9)
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kept constant, while c, reflecting the stimulatory capacity
of the tumour upon the inducible vasculature, has been
perturbed by a uniform 20 percent either side of the ref-
erence value (Fig. 6b), which was set equal to 5.85 day−1
[31]. Values 5.85 day−1, 7.02 day−1 and 4.68 day−1, were
thus assigned to c. According to Fig. 6b an increased
value of parameter c would result in higher angiogenic
stimulatory capacity of the tumour and thus to its faster
growing, as expected based on Eq. (8). Similarly, de-
creasing c would result in a slower growing tumour, a
conclusion that is also corroborated in a graphical way
(Fig. 6b). The great impact of perturbing c in the actual
value of the plateau attained by the tumour is presented
in Table 2.
Perturbing parameter d All parameters remain constant,
while d, reflecting endogenous inhibition of further
angiogenesis, has been perturbed by a uniform 20 per-
cent either side of the reference value (Fig. 6c), which
was set equal to 0.00873 day−1 · mm−2 [31]. Thus,
values 0.00873 day−1 · mm−2, 0.010476 day−1 · mm−2
and 0.006984 day−1 · mm−2 have been assigned to d. It
is expected that high values of parameter d lead to tu-
mours with high endogenous angiogenesis inhibition
and hence, to slower tumour growth. In a similar way,
lower values of d are expected to correspond to tu-
mours with less angiogenesis inhibition and thus, to
faster growing tumours. In accordance with the previ-
ous statement, Fig. 6c displays the timecourse of a
slower growing tumour attaining a lower plateau for
the maximal value assigned to d and the time course of
a faster growing tumour attaining a higher plateau for
the minimal value assigned to d. The impact of per-
turbing d on the actual value of the plateau attained by
the tumour is presented in Table 2.
As it has been expected based on Eq. (9) reading the
mathematical formulation of steady state solution of theODE system, Fig. 6 and Table 2 render c and d, i.e. the
parameters related to the total amount of angiogenic
stimulators and inhibitors respectively, the sole modula-
tors of the value of the plateau attained by the tumour,
while λ1 appears to be the main modulator of the time-
point at which the tumour reaches the plateau.
Two extra sets of simulations have been conducted in
order to determine in a graphical way the “shortest path”
to a more and a less aggressive tumour respectively, by
varying one parameter at a time. It is noted that for con-
venience, the graphs corresponding to the different var-
ied parameters are plotted in the same coordinate
system for each study performed. Thus, we have pro-
ceeded with the simultaneous demonstration of the ef-
fect of perturbing λ1 and c by the percentage of +20 %
and d by the percentage of −20 % of the respective refer-
ence values (Fig. 7a), so as to increase the aggressiveness
of the tumour. Subsequently, we present the effect of
perturbing λ1 and c by a uniform −20 % and d by a uni-
form +20 % of the respective reference values (Fig. 7b)
in order to construct a less aggressive tumour.
The results that are presented with the use of graph-
ical representation suggest that in the specific region of
parameter space, d, the parameter that reflects the concen-
tration of angiogenesis inhibitors is the most sensitive par-
ameter to changes that create a more aggressive tumour,
while c, the parameter that relates to angiogenic stimulatory
capacity, seems to be the most sensitive parameter to
changes that create a less aggressive tumour. This suggests
that antiangiogenic treatment aiming at reducing the
amount of angiogenic stimulators (e.g. treatment with
antiangiogenic agent bevacizumab), could be a more ef-
ficient strategy than increasing the amount of angio-
genic inhibitors in the tumour (e.g. administration of
angiostatin). Of course, further investigation is needed
for this claim to be corroborated.
A closer inspection of the two comparative graphs
reveals a dependence of the sensitivity on the final
Fig. 7 The shortest path to a more aggressive tumour and towards a less aggressive tumour. a The effect of perturbing λ1, c and d by 20 % in
order to construct a more aggressive tumour. b The effect of perturbing λ1, c and d by 20 % in order to construct a less aggressive tumour. c Selection
of an earlier end-point (day 10): the effect of perturbing λ1, c and d by 20 % in order to construct a more aggressive tumour. d Selection of an earlier
end-point (day 15): the effect of perturbing λ1, c and d by 20 % in order to construct a less aggressive tumour
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final timepoint in the initial phase of the tumour (e.g.
day 10 in the “towards a more aggressive tumour” sce-
nario and day 15 in the “towards a less aggressive
tumour” scenario), λ1 appears to be the most influen-
tial input parameter (Fig. 7c, d). This behaviour sug-
gests that in the early vascular phase, the primary
factor driving the time evolution of the overall system
is the intrinsic features of the tumour, reflected by
parameter λ1 which is independent of the angiogenic
compartment. However, an untreated tumour will
eventually reach a point in time where it has become
sufficiently large and the parameters that are related
with the angiogenic process will become the most in-
fluential to the tumour development. Hence, in the
latter case, the application of antiangiogenic treatment
would be more efficient while in the former case,
treatment methods that target directly the tumour
compartment such as the typical chemotherapy agents
acting cytotoxically on cancer cells would be probably
more effective. Again, further investigation is neces-
sary for the confirmation of this claim.
It is a well-recognized fact that the angiogenic potential
of a tumour is regulated by a dynamic balance between
endogenous proangiogenic and antiangiogenic factors.Therefore, a significant step would be to gain deeper
insight into the quantitative effect of each one of the rele-
vant parameters (c and d respectively) as well as their
combined effect on the aggressiveness of the tumour as
reflected by the value of the attained tumour plateau. To
this end, we have made use of the equation giving the
steady state solution of the unperturbed growth module of
the dynamical system (Eq. (9)). This further study of the
dependence of the plateau value attained by an untreated
tumour on c, d (λ1 does not affect it) is of great signifi-
cance since it could determine boundaries for the param-
eter values that yield a biologically realistic plateau for
simulating actual clinical tumours. Based on Eq. (9), the
value of tumour plateau can be considered as a function
of parameter c, a or d, with the rest of parameters involved
in the computation set equal to reference values. Thus,
the effect of each one of these parameters on the value
of tumour plateau can be studied by varying the value
of parameter of interest. Regarding the range of parameter
values used for the needs of parameter analysis (see
Table 3), an upper bounded tumour volume plateau by an
order of magnitude of 106 (mm3) has been assumed in ac-
cordance with cases regarding mice tumours encountered
in literature [31] as well as with the plateau value calcula-
tions from local fitting results to experimental tumour
Table 3 Free growth-related parameters involved in the
calculation of tumour volume plateau and range of values
that yield biologically acceptable tumour behaviour
Parameters Range of values Units
c [0.933 – 87.3] day−1
d [0.000585 - 0.054] day−1 · mm−2
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following section. A further constraint has been imposed
by assuming that in the untreated growth context no self-
regressing vasculature can occur and thus, carrying cap-
acity is required to be an increasing function (yielding a
lower boundary of c value and an upper boundary of d
value).
Figure 8 shows the effect of parameter c on the tumour
volume plateau. Once more, it is graphically corroborated
that higher values of the parameter that reflects the en-
dogenous angiogenic stimulation lead to higher tumour
volume plateau values. The gradient of the tumour
volume plateau function varies smoothly along the
curve suggesting the non-existence of a specific area
exhibiting greater sensitivity throughout the whole
range of values considered for c.
In sharp contrast, Fig. 9 demonstrates a more pro-
nounced effect on the tumour volume plateau for smaller
values of parameter d, reflecting the endogenous inhibition
of angiogenesis. Indeed, as the initial steepness of the curve
suggests (displayed in a logarithmic-linear scale in Fig. 9a0 10 20 30 40
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Fig. 8 The effect of tumour angiogenesis stimulators on the tumour volum
dependence of tumour volume plateau value on the parameter reflecting
rate of carrying capacityand in linear-linear scale in Fig. 9b), a variation of param-
eter d over the initial 22.47 % of the domain of the function
i.e. [0.000585, 0.012005] causes the tumour volume plateau
size to span two orders of magnitude (i.e. approximately
66.67 % of the function’s range).
Finally, in order to capture the dynamics of the molecu-
lar competition between endogenous proangiogenic and
antiangiogenic factors in a tumour, we have proceeded
with the three-dimensional visualization of the joint effect
of parameters c and d on the value attained by the tumour
volume plateau (Fig. 10).
At first glance, the counteracting effect of endogenous
proangiogenic and antiangiogenic factors becomes obvious,
with the most aggressive tumours (in terms of plateau
value) being characterized by higher c values combined
with lower d values. Virtual tumours with lower values of
parameter d are more aggressive than those with higher d
values. This difference remains approximately constant as c
value increases. Similarly, tumours characterized by higher
values of parameter c are more aggressive than those with
lower c values with the difference remaining nearly con-
stant over the entire d value range considered. Both param-
eters have a comparable effect on tumour value plateau
throughout the range of values considered with the more
pronounced one caused by parameter c. Finally, in accord-
ance with the conclusions previously drawn (Figs. 8 and 9),
the influence of parameter c retains the same character over
the entire value range considered. By contrast, parameter d
demonstrates a sensitive behaviour on the tumour volume50 60 70 80 90
/day)
e plateau. Graphical representation of the function describing the
the impact of endogenous angiogenesis stimulators (c) on the growth
Fig. 9 The effect of tumour angiogenesis inhibitors on the tumour volume plateau. Graphical representation of the function describing the
dependence of tumour volume plateau value on the parameter reflecting the impact of endogenous angiogenesis inhibitors (d) on the growth
rate of carrying capacity a. displayed in a logarithmic-linear scale b. displayed in a linear-linear scale
Argyri et al. Biology Direct  (2016) 11:12 Page 17 of 31plateau for smaller d values with the sensitivity decreasing
as d values increase. The curves characterized by constant
d = 0.00873 day−1 · mm−2 and constant c = 5.85 day−1
correspond to Figs. 8 and 9 respectively.
Local fitting results
Experiment 1: In the context of a monotherapy antitu-
mour efficacy study, twenty mice bearing KPL-4 human
estrogen receptor-negative breast adenocarcinoma xe-
nografts were divided into a vehicle and a treatment
group (10 animals per group) dosed with bevacizumab0
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Fig. 10 The combined effect of tumour angiogenesis stimulators and inhib
of the combined effect of parameter c reflecting the action of endogeno
endogenous angiogenic inhibitors on the value of the plateau attained b
attained tumour volume plateauat 5 mg/kg twice weekly intraperitoneally [60]. The results
of the local fitting are presented in Table 4 and Fig. 11.
Experiment 2: A second dataset of twenty mice bearing
KPL-4 human estrogen receptor-negative breast adenocar-
cinoma xenografts has been divided into a vehicle and a
treatment group (10 animals per group) dosed with beva-
cizumab at 5 mg/kg twice weekly intraperitoneally [60].
The specific experiment has been conducted in the con-
text of a combination treatment antitumour efficacy study
but only the free growth – related and bevacizumab
monotherapy-related data were exploitable by the model.0
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itors on the tumour volume plateau. Three-dimensional visualization
us angiogenic stimulators and parameter d reflecting the action of
y the tumour. Different colours correspond to distinct values of
Table 4 Parameter values that have been specified by locally fitting the vascular tumour growth model to experimental data
extracted from [60]
Study Experimental group λ1 c d β p K0 RMSE FOO
day−1 mg/day · mm3p · kg day−1 · mm−2 mm3p - mm3 mm3
Dataset 1 Control 4.7129 0.1519 0.0015 - - 159.4476 10.7552 3.31 · 10−2
Treatment 0.6701 0.0991 0.0015 1 4.0606 76.0920 7.0026 1.5 · 10−3
(5 mg/kg)
Dataset 2 Control 0.1340 1.1503 0.0088 - - 650 13.3087 1.12 · 10−2
Treatment 0.1049 0.5236 0.0088 1.4456 3.8916 358.2054 11.7711 6.72 · 10−5
(5 mg/kg)
First-order optimality (FOO) is a measure of the closeness of the solution to the optimum
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Fig. 11.
Experiment 3: Four groups of athymic mice bearing
H226 xenografts (lung cancer cells) were treated with
IgG (control) or 3 dose levels of bevacizumab (1, 5 and
25 mg/kg intraperitoneally) twice weekly for a total of 9
doses (3 mice per group) [61]. The results of the local
fitting are presented in Table 5 and Fig. 12.
Experiment 4: Four groups of athymic mice bearing
SCC1 xenografts (head and neck cancer cells) were treated
with IgG (control) or 3 dose levels of bevacizumab (1, 5
and 25 mg/kg intraperitoneally) twice weekly for a total of
9 doses (3 mice per group) [61]. The results of the local
fitting are presented in Table 5 and Fig. 13.
Experiment 5: Xenograft mouse tumour models of
colon cancer cell line HCT116 were divided in a control
and a treatment group. The treatment group received
15 mg/kg of bevacizumab intraperitoneally twice weekly
for four weeks, while the control group received the
same amount of nonspecific murine IgG antibody [62].
The results of the local fitting are presented in Table 6
and Fig. 14a.
Experiment 6: Xenograft mouse tumour models of
colon cancer cell line HT29 were divided in a controlFig. 11 Fitting the model to breast cancer data. Graphical representation o
bevacizumab treatment model to experimental data concerning KPL-4 hum
were extracted from [60]: a In the context of a bevacizumab monotherapy stuand a treatment group. The treatment group received
15 mg/kg of bevacizumab intraperitoneally twice weekly,
while the control group received the same amount of
nonspecific murine IgG antibody [62]. The results of the
local fitting are presented in Table 6 and Fig. 14b.
Experiment 7: Xenograft mouse tumour models of
colon cancer cell line HCP40, a cell line derived by ex-
posing HCT116 cells to sublethal periods of hypoxia
three times weekly for 40 exposures, were divided in a
control and a treatment group. The treatment group re-
ceived 15 mg/kg of bevacizumab intraperitoneally twice
weekly, while the control group received the same
amount of nonspecific murine IgG antibody [62]. The
results of the local fitting are presented in Table 6 and
Fig. 14c.
Experiment 8: Xenograft mouse tumour models of colon
cancer cell lines HP40, a cell line derived by exposing
HT29 cells to sublethal periods of hypoxia three times
weekly for 40 exposures, were divided in a control and a
treatment group. The treatment group received 15 mg/kg
of bevacizumab intraperitoneally twice weekly, while the
control group received the same amount of nonspecific
murine IgG antibody [62]. The results of the local fitting
are presented in Table 6 and Fig. 14d.f the fitting results of the vascular tumour growth and response to
an estrogen receptor-negative breast adenocarcinoma xenografts that
dy, b In the context of a bevacizumab combination treatment study
Table 5 Parameter values that have been specified by locally fitting the vascular tumour growth model to experimental data
extracted from [61]
Cell line Experimental group λ1 c d β p K0 RMSE FOO
day−1 mg/day · mm3p · kg day−1 · mm−2 mm3p - mm3 mm3
H226 (lung cancer cells) Control 0.1028 0.7264 0.0075 - - 208.6162 16.7273 2.57 · 10−1
Treatment 1 0.1028 0.3982 0.0075 1 4.9963 183.4523 22.2226 10−3
(1 mg/kg)
Treatment 2 0.1028 0.3214 0.0075 1 5.6544 118.7044 8.0860 1.12 · 10−4
(5 mg/kg)
Treatment 3 0.1028 0.1735 0.0075 1 5.6024 320.1562 21.1671 3.31 · 10−4
(25 mg/kg)
HSCC1 (head and neck cancer cells) Control 0.0444 3.3548 0.0198 - - 23.6087 10.2691 9.5 · 10−2
Treatment 1 0.0444 1.4969 0.0190 1 5.0006 38.9545 27.8009 1.2 · 10−3
(1 mg/kg)
Treatment 2 0.0444 1.4895 0.0190 1 6.0014 30.6914 27.8653 6.88 · 10−4
(5 mg/kg)
Treatment 3 0.0444 0.8864 0.0190 1 5.5002 46.0371 9.7061 7.65 · 10−5
(25 mg/kg)
First-order optimality (FOO) is a measure of the closeness of the solution to the optimal
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mental data supports the validity of the underlying model.
At this point it should be stressed that since the model
presented focuses only on bevacizumab monotherapy, the
body of experimental data that could be used in order to
test the model was quite limited. Therefore, we had to
make use of this limited experimental data body in
order to fit the model. Taking this into account, the
results and conclusions presented are to be viewed as5 10 15 20
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Fig. 12 Fitting the model to lung cancer data. Graphical representation of
bevacizumab treatment model to experimental data concerning lung tumopreliminary signs of evidence rather than definitive
validated knowledge. Additionally, it should be borne
in mind that due to the complexity of cancer models,
the scarcity and the low quality of experimental/clin-
ical data, the potential danger of overfitting leading to
over-optimistic results is very common.
All results were obtained with a maximum termination
tolerance on the function value equal to 10−6. Following
the evaluation of normalized root mean square error25 30 35 40 45
 (days)
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Fig. 13 Fitting the model to head and neck cancer data. Graphical representation of the fitting results of the vascular tumour growth model to
experimental data concerning head and neck tumour xenografts [61]
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about a few cases where a non-satisfying fit has been ob-
tained (e.g. experiment 3: cell line H226, treatment
group, dose level 25 mg/kg and experiment 4: cell line
HSSC1, treatment group, dose level 5 mg/kg). Among
possible causes could be human error in digitization of
the experimental data with the use of the PlotDigitizer
software and the locality of the selected fitting method.
In particular, local solvers such as the one used in this
case provide the user with a local minimum depending
on the selected starting point, but not necessarily theTable 6 Parameter values that have been specified via locally fitting
extracted from [62]
Cell line Experimental group λ1 c d
day−1 mg/[day · mm3p · kg] day−
HCT116 Control 0.2362 0.4884 0.00
Treatment 0.2362 0.3881 0.00
(15 mg/kg)
HCP40 Control 0.1603 0.5036 0.00
Treatment 0.1233 0.0186 0.00
(15 mg/kg)
HT29 Control 0.2138 0.5061 0.00
Treatment 0.2138 0.3783 0.00
(15 mg/kg)
HP40 Control 0.2966 0.5056 0.00
Treatment 0.2966 0.4356 0.00
(15 mg/kg)
First-order optimality (FOO) is a measure of the closeness of the solution to the optbest or global minimum. This means that had the solver
been initialized at different parameter values than the se-
lected ones [31], better results could have come up. This
claim is also supported by the fact that the aforementioned
fitting difficulty seems to mostly occur in the therapeutic
module of the model and especially in cases of higher dos-
age administration (5–25 mg/kg) where a greater perturb-
ation of free growth parameter values is expected.
It should be noted however, that potential non-uniqueness
of a solution could suggest over-parameterization of a
model. In fact, due to the incomplete quantitativethe vascular tumour growth model to experimental data
β p K0 RMSE FOO
1 · mm−2 mm3p - mm3 mm3
17 - - 194.5946 121.7580 7.35 · 10−1
17 1 5.7777 0.6 74.8503 6.61 · 10−2
13 - - 223.3251 47.8814 1.30 · 10−1
13 0.9062 12.4022 17.2066 9.3102 8.76 · 10−5
17 - - 111.5735 58.1716 2.17 · 10−1
17 1 6.2774 0.6 129.8810 1.5 · 10−3
22 - - 134.0895 100.5007 3.77 · 10−1
22 1 4.5576 23.0272 93.2413 1.33 · 10−1
imum
Fig. 14 Fitting the model to colon cancer data. Graphical representation of the fitting results of the vascular tumour growth model to the
experimental data that were extracted from [62]. Local fitting using xenograft mouse tumour models of colon cancer cell lines a. HCT116
b. HT29 c. HCP40 d. HP40
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pure tumour growth and their interaction and at the
same time to the need for a more detailed description of
certain fundamental qualitative mechanisms which col-
lectively constitute the nature of phenomenon of cancer,
some degree of over-parameterization seems to be cur-
rently unavoidable. In this case, identifiability analysis
could determine whether the parameters involved in the
system are uniquely estimable from the experimental data
and if not, whether the nonidentifiability is structural or
practical, i.e. it can be overcome with the use of a different
experimental dataset. A discussion on identifiability ana-
lysis can be found in [67–71]. However, it should be noted
that as at this point in time the exact boundaries of the re-
gion of multidimensional parameter space yielding bio-
logically acceptable tumour volume behaviour have not
yet been determined, this kind of analysis is rather prema-
ture. In particular, even if the system was proved noni-
dentifiable it could still be valid as in real-life
applications, such as the one studied in this paper, what
we seek for is not a solution unique for the parameter
space in its entirety, but a solution unique in a specific
parameter subspace that includes valid parameter
values for e.g. a human cancer patient. Even if more
than one equally good solutions come up for a specificdataset, the availability of further clinical data which
would allow us to impose constraints on the optimal
solution narrowing down the potential solutions could
be of vital importance. Eventually, functional data such
as positron emission tomography (PET) or functional
magnetic resonance imaging (fMRI) and histopatho-
logical data with the help of which the modeller can
gain insight into the case-specific appropriate param-
eter space will be able to assist the determination of a
personalized and as such unique solution.
In order to address a part of the aforementioned limited
discrepancies, multiple actions need to be taken. First of
all, extra experimental datasets should be extracted from
relevant literature, ideally concerning actual clinical pa-
tients and directly available so as not to risk human error
due to the digitization of the experimental data with the
use of PlotDigitizer software, in order to elucidate the
exact reasons of the occurrence of these incidents and act
accordingly. Another obviously significant task would be
to conduct global fitting of the vascular tumour growth
model so as to attempt to determine solutions for the
problematic cases of fitting encountered so far. Currently,
the Multistart solver in Global Optimization Toolbox is
used in conjunction with Matlab functions lsqnonlin,
fmincon and fminsearch.
Table 7 Normalized root-mean-square error calculated for each experimental dataset utilized in the context of model fitting
Cell line Reference Experimental group Range of experimental values RMSE NRMSE
KPL-4 (Bevacizumab monotherapy study) [60] Control 500.25 10.76 2.15 %
Treatment 83.23 7.00 8.41 %
(5 mg/kg)
KPL-4 (Bevacizumab combination
treatment study)
[60] Control 639.84 13.31 2.08 %
Treatment 165.70 11.77 7.10 %
(5 mg/kg)
H226 [61] Control 603.07 16.73 2.77 %
Treatment 1 241.23 22.22 9.21 %
(1 mg/kg)
Treatment 2 177.17 8.09 4.57 %
(5 mg/kg)
Treatment 3 76.32 21.17 27.74 %
(25 mg/kg)
HSCC1 [61] Control 504.05 10.27 2.04 %
Treatment 1 188.87 27.80 14.72 %
(1 mg/kg)
Treatment 2 164.08 27.87 16.99 %
(5 mg/kg)
Treatment 3 125.12 9.71 7.76 %
(25 mg/kg)
HCT116 [62] Control 2902.71 121.76 4.19 %
Treatment 1411.98 74.85 5.30 %
(15 mg/kg)
HCP40 [62] Control 2992.56 47.88 1.60 %
Treatment 178.66 9.31 5.21 %
(15 mg/kg)
HT29 [62] Control 2381.34 58.17 2.44 %
Treatment 1276.84 129.88 10.17 %
(15 mg/kg)
HP40 [62] Control 2484.60 100.50 4.04 %
Treatment 1454.25 93.24 6.41 %
(15 mg/kg)
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The main focus of this work is to study and extend a
continuous approach describing vascular tumour growth
under angiogenic signalling presented in [43]. To this end,
the pharmacokinetic properties of bevacizumab have been
incorporated into the model and the monotherapy effect
has been simulated for the specific angiogenic inhibitor,
which probably is the most popular representative of the
wider family of antiangiogenic agents in clinical practice.
Additionally, the model has been modified in order to re-
produce the asymptotic behaviour of tumour volume in
the theoretical case of a total destruction of the tumour
neovasculature. The results produced by the model havebeen thoroughly studied and reveal qualitative similarities
with experimental observations. An initial exploratory
parametric analysis has been conducted, in order to gain
insight into the free growth behaviour of a vascularized
tumour. In this context, the role of endogenous proangio-
genic and antiangiogenic factors in tumour evolution has
been examined as well as their combined effect on the
eventually attained tumour volume plateau. Insight into
the significance of a tumour size - specific treatment
planning has been revealed. The conducted parameter
analysis suggests that an initial chemotherapeutic inter-
vention when the tumour is sufficiently small, followed
by antiangiogenic treatment when the tumour reaches
Argyri et al. Biology Direct  (2016) 11:12 Page 23 of 31a critical size would be the most efficient treatment
strategy. This does not contradict the current clinical
practice suggesting treatment combining antiangiogenic
treatment with chemotherapeutic agents but highlights
the potential significance of a prior chemotherapeutic
intervention. Further investigation is necessary to con-
firm this claim. Furthermore, local fitting of the vascu-
lar tumour growth model to actual experimental data
concerning the in vivo study of solid tumours has been
performed so as to acquire an initial confirmation that
the underlying mathematical model [31, 43] is actually
tailored to the nature of the problem under study. The
global fitting of the model is currently underway. The
successful reproduction of the results of a series of
in vivo experiments in mice treated with bevacizumab
lends support to the underlying model.
A meaningful extension of this work would be to
simulate the effect of combination treatment consisting
of both antiangiogenic treatment and cytotoxic agents.
In this case, the model should be modified so as to ac-
count for the synergistic effect of the concomitant ad-
ministration of antiangiogenic and chemotherapeutic
treatment. Another interesting modification, would be to
consider a saturation effect based on the existence of the
concept of optimal biological dose reported in relevant
literature. Finally, the consideration of diverse cell popu-
lations would allow the modeller to exploit potentially
available histological data concerning cell composition of
the tumour and link it with the response to a specific
treatment scheme.
At this point it should be noted that stochasticity ap-
pears to be an important characteristic of malignant
tumour growth and response to treatment. Despite the
fact that the model presented is a deterministic one, it
could also be used in a stochastic context as follows: in
order to compare candidate treatment schemes and/or
schedules in silico, several possible combinations of
parameter values lying around their apparently most
probable estimates have to be constructed so as to
cover the abstract parameter space as best as possible.
Code executions have to be performed for all these se-
lected parameter combinations. If, for example, the
clinical question addressed is “Which one of the two
candidate treatment schedules denoted by I and II is
the most promising for a given patient?” simulations
have to be run for both schedules I and II and for all
parameter value combinations selected. If based on the
simulation predictions schedule I outperforms schedule II
for a sufficiently large percentage of the total parameter
combinations considered, say 90 %, then there is ground
to suggest adoption of schedule I [72]. It should also be
mentioned that a number of predominantly stochastic
tumour growth models [73], vascular tumour growth
models [74] and angiogenesis models [75] have alsoappeared in literature. However, the majority of such
models has not been developed bearing targeted antian-
giogenic treatment in mind.
Our ultimate goal is to simulate the spatiotemporal re-
sponse of clinical tumours to various treatment schemes
and schedules in the patient individualized context. This
extremely challenging task entails the exploitation of
multiscale clinical data, for the purpose of conducting
thorough fitting and validation studies of the model
and obtaining parameter estimates representative of the
human patient. An invaluable help toward obtaining
patient-specific predictions is expected to be provided by
the identification of potential biomarkers of bevacizumab
response, emerging from numerous clinical trials. It
should be noted that the work presented is also posi-
tioned within the large scale integrated project CHIC
[Computational Horizons In Cancer (CHIC): Developing
Meta- and Hyper-Multiscale Models and Repositories for
In Silico Oncology (FP7-ICT-2011-600841)]. The latter
aims at developing cutting edge ICT tools, services and se-
cure infrastructure to foster the development of elaborate
and reusable integrative models (hypermodels) and larger
repositories so as to demonstrate benefits of having both
the multiscale data and the corresponding models readily
available. In this context, the presented model constitutes
one of the component models of the CHIC model reposi-
tory, with the ultimate goal of being combined with other
CHIC models to form clinically-relevant hypermodels.Reviewers’ comments
Reviewer's report 1: Dr Leonid G Hanin, Department of
Mathematics, Idaho State University
General Comments
1. The results of the paper seem to suggest that under
antiangiogenic treatment the volume of a tumor will al-
ways eventually increase and reach a high-level plateau.
Then why does one need such treatment? Isn’t the goal
of antiangiogenic therapy to shrink the tumor to the
avascular level and induce dormancy?
Authors’ response: Based on the originally expected effect
of antiangiogenic treatment, the rather obvious goal would
be to render a tumour avascular and induce quiescence.
However, it should be noted that following years of antian-
giogenic agents’ use in the clinical setting, several possible
explanations of the actual effect of this kind of treatment
have been proposed. Apart from the partial regression of
tumour vasculature (von Baumgarten et al. 2011), one of
the most widely accepted theoretical explanations is based
on the effect of vascular normalization (Jain, 2003). The
latter may lead to a more efficient access of the chemo-
therapeutic drug to tumour cells which is administered in
conjunction with antiangiogenic treatment. It is also pointed
out that the antiangiogenic agent is in fact cytotoxic per se
Argyri et al. Biology Direct  (2016) 11:12 Page 24 of 31for certain tumour types (Drevs, 2008). Therefore, the final
treatment outcome may prove to be a quite complex one.
Additionally, it should be stressed that certain theoretical
explanations proposed up to now appear to be at least
partly mutually conflicting. Therefore, further experimen-
tal, clinical and in silico investigation is needed in order to
clarify the open issues.
Regarding the eventual tumour repopulation, this
appears to be inevitable in cases where even a single
cell has survived the treatment. However, even a transient
tumour volume decrease could render an inoperable
tumour to an operable one, offering the patient a chance to
eventually cure the disease. Finally, even though we agree
with Dr Hanin in that ideally, the goal of antiangiogenic
treatment would be to render the tumour avascular, it
should be taken into account that even if in several cases
this kind of therapy does not induce tumour volume de-
crease at all, due to intrinsic or evasive tumour resistance,
the valuable effect of tumour growth delay is still obtained.
From the clinician’s viewpoint, this effect is considered
valuable because not only it extends the patient’s lifespan
but it also enhances the patient’s quality of life.
Drevs J: VEGF and angiogenesis: implications for breast
cancer therapy. European Journal of Cancer Supplements
2008, 6:7–13.
Jain RK: Molecular regulation of vessel maturation.
Nature Medicine 2003, 9:685–693.
von Baumgarten L, Brucker D, Tirniceru A, Kienast Y,
Grau S, Burgold S, Herms J, Winkler F: Bevacizumab
Has Differential and Dose-Dependent Effects on Glioma
Blood Vessels and Tumor Cells. Clinical Cancer Re-
search 2011, 17:6192–6205.
2. P. 22. The fact that in the absence of treatment
tumor volume V may decrease (that is, V may become
larger than the carrying capacity K) is somewhat troub-
ling. This probably means that model (1)-(2) is inad-
equate and should be changed through a more careful
study of pro- and anti-angiogenesis forces. Overcoming
this problem by imposing a restriction on parameter
values seems artificial.
Authors’ response: This kind of behaviour occurs in
two cases. First, if the user selects biologically invalid ini-
tial values (V0, K0) i.e. K0 < V0. Second, if the user selects
a biologically irrelevant combination of parameter values
involved in the model. For example, by setting parameter
c as equal to zero, one creates a tumour with no endogenous
angiogenic stimulation and thus a self-regressing tumour.
However, in both cases in which the model yields a be-
haviour that is obviously incompatible with clinical
reality, the input would be just nonsensical since it
would not correspond to a biologically valid behaviour.
These are restrictions imposed by the biological reality
and not artificial constraints. The model is only a tool
and the quality of input always determines the qualityof output. In an eventual future integration of the model
into a clinical decision support system appropriate in-
put checkers will be included in order to minimize the
chances for nonsensical input.
3. I do not understand the motivation behind local
parameter optimization. When parameters are fit to the
observed time course of tumor volume they ideally
should be optimized globally (under natural constraints
like positivity) and the initial values of model variables
should also be subjected to global optimization. What
prevents the authors from doing this?
Authors’ response: We completely agree with Dr Hanin
in that global fitting of the model is clearly superior to
local fitting, especially if one takes into account the frequent
presence of multiple local minima rendering the outcome of
a local investigation uncertain. However global fitting re-
quires the investigation throughout a finite parameter space.
In our case, the physical constraint of non-negativity alone
could not sufficiently narrow the range of parameter values.
This difficulty still leaves the search of parameter space in
its entirety an extremely computationally challenging task.
Indeed, although the relevant code had already been devel-
oped by us, we did not proceed with its use as the initial re-
sults were discouraging in terms of computational demands.
Hence, instead of constraining the problem in a random
and arbitrary way, as a first step we performed the in-
vestigation of the local behaviour of the model around
the available reference values. Of course, as we also
stress in the manuscript, all results and conclusions
drawn in the context of the local fitting of the model are
to be viewed as preliminary signs of evidence rather
than definitive validated knowledge.
4. Some parameters of models (1)-(2) and (5)-(6) are
non-identifiable. For example, in the absence of treat-
ment (I = 0) the models depend on the ratio c/α. Also, in
the case p = 0 considered in the paper the treatment
model depends in reality not on three parameters c, α, β
but rather on two combinations, c(β + 1) and α(β + 1), of
these parameters. Therefore, model parameters cannot
be fixed arbitrarily and varied or optimized independ-
ently. In particular, the choice α = β = 1 made in the
paper forces the authors to deal from the outset with a
sub-optimal model. Model non-identifiability and the
resulting overparameterization may explain various trou-
bles that the authors had with parameter estimation. To
be useful, the models should be formulated in terms of
identifiable combinations of the original parameters. For
a general discussion of structural identifiability for both
deterministic and stochastic models, the authors are
referred to the following paper:
L.G. Hanin (2002), Identification problem for stochastic
models with application to carcinogenesis, cancer detec-
tion and radiation biology, Discrete Dynamics in Nature
and Society 7(3):177–189.
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model sub-optimality, it should be noted that both α and
β were set equal to 1 as in (Poleszczuk et.al [43]), only
for demonstration purposes in the context of the Results
and Discussion subsection entitled “Indicative tumour
growth patterns”. For the needs of the automated fitting
process, parameter β has been allowed to fluctuate
around the initial value β = 1. Thus, all β values appearing
in Tables 3, 4, and 5 have been estimated via the least
squares solver. The reason why many of those values re-
main equal to 1 is that high values of parameter p have
rendered parameter β insensitive to perturbations of its
value. Thus, the least squares solver minimized the cost
function using the rest of the parameters that were more
sensitive comparing to β.
Regarding the identifiable parameter combinations, we
agree with Dr Hanin that this kind of analysis should be
performed and we plan to conduct it in our future work.It is
noted that the work presented is only an initial approach to
the highly complex and demanding problem of simulating
vascular tumour growth under bevacizumab treatment and
adapting the simulation model to real animal and/or
clinical data. The available data is very limited and
mostly incomplete. Therefore, the manuscript aims at
contributing to paving the way for the development of a
clinically useful model and its in vivo fitting rather than
providing an extensively validated and ready to use
model. In this context, the effect of each individual par-
ameter corresponding to a given bioprocess has been
studied in order to gain some initial insight into the
physical behaviour and the physical understanding of
the model. As we also mention above, we plan to continue
the exploration of the parameters’ effects and eventual
interdependences in future work. The same applies to the
extension of our initial fitting methodology from estimating
individual parameter values to estimating values of identi-
fiable parameter combinations.
Regarding identifiablility analysis, as we also mention
in our response to Prof Radivoyevitch, it is a valuable
tool to evaluate the predictive power of the model since
the outcome of the model prediction is dependent on the
identifiability of the parameters involved. However, in our
case, identifiability analysis was considered premature, in
the sense that the exact boundaries of the multidimen-
sional parameter subspace yielding biologically acceptable
tumour volume behaviour have not been yet determined.
Hence, even if the system proved to be nonidentifiable we
think it could still be valid for the following reason. In real-
life applications such as the one studied in this manuscript,
what we actually seek for is not a unique solution for the
parameter space in its entirety, but a unique solution in a
specific parameter subspace that includes valid parameter
values for e.g. a human cancer patient. Finally, we have in-
cluded the source suggested by Dr Hanin in the relevantdiscussion in p.34 of the subsection entitled “Local fitting
results”.
Poleszczuk J, Bodnar M, Foryś U: New approach to
modeling of antiangiogenic treatment on the basis of
Hahnfeldt et al. model. Math Biosci Eng 2011, 8:591–603.
5. The transition from model (3)-(4) in the original
paper to model (7)-(8) in its revision was triggered by
my comment about inconsistency of model (3)-(4). Because
Biology Direct is an open review journal, this should prob-
ably be acknowledged.
Authors’ response: We thank Dr Hanin for his important
remark. We completely agree. Our updated approach along
with an explicit acknowledgement to Dr Hanin is included
in the subsection entitled “A continuous approach to model-
ling the mechanism of action of antiangiogenic treatment
applied on a vascularized tumour” which is part of the sec-
tion “Methods.” More precisely, the following text has been
inserted “Prompted by a remark made by Dr. Leonid Hanin
in his capacity as a reviewer of the present manuscript, we
have proceeded to a correction of the asymptotic behaviour
of the system as the drug concentration tends to infinity
(I(t)→∞). According to our initial gross assumption and in
agreement with the asymptotic behaviour of the ODE model
developed by Hahnfeldt et al. (1999) and Poleszczuk et. al
[43], the tumour volume tends to zero as I(t)→∞. This ap-
pears to be acceptable as a first approximation. However,
we have adopted Hanin’s suggestion to take into account the
refined mathematical observation that as I(t)→∞ the
tumour volume should tend to V*. V* corresponds to the
critical avascular tumour volume.” In addition, Dr Hanin is
specially acknowledged for the same remark in the Acknowl-
edgements section.
Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L: Tumor
development under angiogenic signaling: a dynamical
theory of tumor growth, treatment response, and post-
vascular dormancy. Cancer Res 1999, 59:4770–4775.
Poleszczuk J, Bodnar M, Foryś U: New approach to
modeling of antiangiogenic treatment on the basis of
Hahnfeldt et al. model. Math Biosci Eng 2011,
8:591–603.
6. Eqs. (3) and (4) were derived in [28] on certain bio-
logical grounds. I do not see why the same logic that led
to relationships between V and K also holds for the
quantities V-V* and K-V*.
Authors’ response: We thank Dr Hanin for his remark.
Indeed, the modified equations are not derived on the
exact same basis as the initial ones. The slightly modified
assumption behind the updated equations suggests that
the amount of angiogenic stimulators secreted by the
tumour does not actually depend on the entire tumour
volume V but, instead, on the part of tumour volume
that has been developed following the angiogenic switch
i.e. on the quantity V-V*. This is biologically plausible,
if we take into account that the angiogenic switch, when
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actually the moment at which the tumour begins to
overexpress angiogenic stimulators (Hanahan et al.
[49]). In other words, once in the vascular phase during
which the model is applicable, the part of the tumour
volume developed prior to the triggering of the angiogenic
switch does not contribute to the secretion of proangio-
genic factors and subsequently to the growth of carrying
capacity. Similarly, angiogenic inhibitors are assumed to
depend on the quantities V-V* and K-V*.
We have added a discussion regarding the impact that
our modification has on the initial assumptions in p.14
of the Methods subsection entitled “A continuous approach
to modelling the mechanism of action of antiangiogenic
treatment applied on a vascularized tumour.”
Hanahan D, Weinberg RA: Hallmarks of Cancer: The
Next Generation. Cell 2011, 144:646–674.
7. Is it true that every solution of system (3)-(4) converges
to the steady-state solution? Could there be oscillatory
solutions? These are important questions that should
be addressed from the very beginning.
Authors’ response: Poleszczuk and his colleagues (2011)
have analysed the dynamics of the core of the model for the
case of constant treatment. According to this analysis, there
is a sufficient condition for the existence of a unique steady
state in ℝ+
2 for the ODE system. Clearly, there may also be
a unique steady state solution in ℝ+
2, with no fulfilment of
the specific condition. Poleszczuk et al. have proved that if
the positive steady state for the system is unique in ℝ+
2
then it is globally stable in ℝ+
2. In particular, according to
Poincare- Bendixson theorem any solution tends to either a
steady state or to a closed orbit. However, with the use of
Dulac-Bendixson criterion they conclude to the non-
existence of a closed orbit.
Although we agree with Dr Hanin in the significance of
the qualitative study of the dynamical system, for the
initial local exploration of the physical behaviour of the
model (via parameter analysis and local fitting) which
was the aim of this work, we felt that a bifurcation analysis
was out of scope for the time being. However, we intend to
conduct this kind of analysis in the near future.
Poleszczuk J, Bodnar M, Foryś U: New approach to
modeling of antiangiogenic treatment on the basis of
Hahnfeldt et al. model. Math Biosci Eng 2011, 8:591–603.
8. The structure of the treatment term in Eq. (2)
should be explained. In particular, what is the role of
parameter p and why is it set equal to 0?
Authors’ response: We thank Dr Hanin for his sugges-
tion. Regarding the structure of the treatment term, it is
noted that it came up in (Poleszczuk et al. [43]) based on
the solution of a diffusion equation for the concentration
of angiogenic stimulators. This in turn was based on spe-
cific approximations and underlying assumptions that
are listed in the manuscript. There is a qualitativedescription of all significant steps of the modification per-
formed by Poleszczuk et al. in the Methods subsection en-
titled “A continuous approach to modelling the
mechanism of action of antiangiogenic treatment applied
on a vascularized tumour” and specifically in p.12. Re-
garding the mathematical details, the reader is referred
to (Poleszczuk et al. [43]).We chose not to repeat the
presentation of all calculations to avoid overburdening
the reader with information that is thoroughly explained
in already published work.
The p parameter was introduced in the model through
the fifth assumption in p. 10: “The change of drug con-
centration inside the tumour caused by the dysfunctional
vasculature is governed by the proportionality to a
bounded and decreasing function of tumour volume.” In
particular, the function that was used by Poleszczuk
et al. was of the form 1βþVp ; p≥0 . Hence, parameter p
reflects the extent of the abnormal phenotype of tumour
vasculature.
Parameter p was set equal to 0 only for the presenta-
tion needs of indicative results for the following two rea-
sons: a. 0 was one of the values used in (Poleszczuk et al.
[43]) b. 0 was the most suitable value for demonstration
purposes in the sense that it created the more pro-
nounced therapeutic effect for the specific tumour (char-
acterized by the λ1, c and d values in (Hahnfeldt et al.
1999) and the specific treatment scheme which is widely
applied in the context of in vivo experiments. This fact
allowed a straightforward observation of all significant
qualitative features of the simulation.
Finally, an updated, more specific description of the
parameters that were introduced in the system by Pole-
szczuk et al. i.e. α, β and p, can be found in Table 1.
Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L: Tumor
development under angiogenic signaling: a dynamical
theory of tumor growth, treatment response, and post-
vascular dormancy. Cancer Res 1999, 59:4770–4775.
Poleszczuk J, Bodnar M, Foryś U: New approach to
modeling of antiangiogenic treatment on the basis of
Hahnfeldt et al. model. Math Biosci Eng 2011, 8:591–603.
9. P. 36. The authors concluded that when the tumor
is small it should be first treated with cytotoxic chemother-
apy and when it reaches some critical size an antiangiogenic
treatment should be given. This recommendation seems to
be self-defeating, for chemotherapy will shrink the tumor
even further and so the conditions for antiangiogenic treat-
ment will not be met.
Authors’ response: What was meant by this statement
is that at the timepoint of diagnosis, when the clinician
needs to decide on the therapeutic strategy, the optimal
treatment modality should be selected in a size-specific
way. For example, in the case where a tumour is in its
initial stage of vascular development the clinician should
Argyri et al. Biology Direct  (2016) 11:12 Page 27 of 31bear in mind that cytotoxic treatment would be more
efficient comparing to antiangiogenic treatment. How-
ever, it also holds that even though in the short term
chemotherapy will indeed shrink the tumour, eventually,
due to acquired resistance mechanisms, the tumour will
probably start growing again. Hence, the conditions for
antiangiogenic treatment will eventually be met unlessof
course the tumour is surgically excised.
10. P. 37, 2 paragraph. What is described as stochastic
approach is not stochastic at all!
Authors’ response: The sense in which the term “stochas-
ticity” is used in our extended approach outlined in the
Conclusions section is the following: The new “multi-
thread” model for a given patient is made up of a number
of “one-thread” models along with their input parameter
combinations. These parameter combinations are created
by randomly (stochastically) selecting values from the corre-
sponding value distributions. Distribution moments such as
the mean value and the standard deviation in the case of a
normal distribution are provided as input to the “multi-
thread”. The use of random (or more precisely pseudoran-
dom generators) renders this multi-thread model stochastic.
Technical Comments
1. What is λ1? Is it the intrinsic rate of cancer cell div-
ision or the net proliferation rate?
Authors’ response: Parameter λ1 is the net proliferation
rate reflecting both the intrinsic rate of cancer cell div-
ision and cancer cell death induced by non-metabolic
causes such as the directly cytotoxic effect of bevacizu-
mab. Cell death related to the metabolic conditions in
tumour microenvironment is accounted for through the
vascular compartment i.e. Eq. 6.
2. What is tumor vasculature normalization?
Authors’ response: Vasculature normalization is a hy-
pothesis made by Jain in 2001, stating that antiangiogenic
treatment improves both functionally and morphologically
the abnormal structure of tumour vessels. This transient
effect, known as normalization window, results in a more
normal and organized vasculature network and thus
allows chemotherapy to access a larger part of the tumour
and function more effectively. This hypothesis is consistent
with the bulk of clinical data suggesting a synergistic effect
between antiangiogenic treatment and chemotherapy. We
have added a few lines elaborating on tumour vasculature
normalization in p.6 of the Background section.
“In particular, the antiangiogenic treatment effect is be-
lieved … sites due to the high abnormality of tumour
vessels.”
3. P. 6, end of paragraph 1. The meaning of “tumor im-
munity” is unclear. Do you mean tumor immunogenicity?
Authors’ response: Tumour immunity is the precise term
utilized in (Sato [25]). What the specific source considers asenhancement of tumour immunity is a better and easier
access of leukocytes into the tumour parenchyma due to
antiangiogenic treatment - induced vascular normalization.
Hence, antiangiogenic treatment also functions as an ampli-
fier of the reaction of the immune system to the tumour.
However, we agree with Dr Hanin that using the widely ac-
cepted terminology the term immunogenicity would better
express the phenomenon. Therefore, the latter has been used
in the revised manuscript.
Sato Y: Persistent vascular normalization as an alterna-
tive goal of anti-angiogenic cancer therapy. Cancer Sci
2011, 102:1253–1256.
4. Exponent 2/3 is missing in Eqs. (6) and (8).
Authors’ response: We have inserted the missing
exponents.
5. Why do Eqs. (10)-(11) not account for the initial
dose accumulation?
Authors’ response: Eqs. (10)-(11) constitute part of the
solution of the mass balance equations corresponding to
the two-compartmental model for a single intravenous
infusion. As we explain in p. 17 of the Methods subsection
entitled “Inclusion of bevacizumab pharmacokinetic prop-
erties” the pharmacokinetic effect of multiple drug doses is
computed internally in the code, by superpositioning all
drug concentration curves at each simulation timepoint so
as to sum the contribution of current drug dose with the
one of previous administrations. Hence, the initial dose ac-
cumulation which can be observed in Fig. 4 is accounted
for in the code of the pharmacokinetic model.
6. P. 25. “A closer inspection of Fig. 4a reveals that
each time the curve K(t) intersects curve V(t), the mono-
tonicity of the function V(t) alters.” This is obvious from
Eq. 3.
Authors’ response: This is an observation enabling the
reader to grasp the theoretical concept of carrying cap-
acity which is known only to an audience familiar with
population dynamics modelling. For further clarification,
we have added the sentence “This behaviour that can be
easily noticed from Eq. 3 reflects the fact that carrying
capacity is actually defined as the maximal tumour
volume that the current vascular system can support.”
following the above statement.
7. P. 26, Parameter analysis results. The concept of
doubling time pertains to exponential growth. For non-
exponential growth, it is not a well-defined quantity.
Authors’ response: We agree with Dr Hanin. However,
the term “doubling time” was used in the manuscript in
a pointwise sense, aiming at communicating to the reader
a physical interpretation of the role of λ1 parameter. In
particular, taking into account that a Gompertzian curve
can be considered as a piecewise exponential curve, the
doubling time can be determined in a pointwise mode i.e.
at each timepoint. To improve this sentence, we have
rephrased it as follows.
Argyri et al. Biology Direct  (2016) 11:12 Page 28 of 31“Equation (7) shows that the Gompertzian growth con-
stant λ1 is the only parameter that affects tumour growth
rate independently of the angiogenic compartment, making
it thus a direct modulator of the doubling time characteriz-
ing the simulated tumour at each timepoint.”
Comments on Style
1. The paper should be translated from “international
sciencespeak” into normative English. Reading some parts
of the paper was quite painful. Many words are misused,
and many expressions and phrases are awkward or gram-
matically incorrect. They are far too numerous to list.
Monstrous sentences like “To this end, a mechanistic
model monitoring both the tumour and vascular compart-
ment while addressing the targeted nature of the specific
kind of treatment will serve as a vehicle to valuable insight
into anti-angiogenic treatment mode of action” on p. 9 or
“The subsequent step following the development of the
continuous approach describing vascular tumour growth
under angiogenic signalling and its extension via the inclu-
sion of bevacizumab pharmacokinetic properties is cor-
roborating that the mathematical structure of the model
reflects the nature of the problem under investigation” on
p. 20 should be rephrased and broken down into simpler
sentences or dropped altogether. The authors are advised
to consult a native English speaker.
Authors’ response: We have rephrased and shortened
many sentences and we have improved the language of
the manuscript.
2. To prop up their statements about cancer biology,
the authors should refer the reader to biological rather
than mathematical papers (see ref. [3, 4, 7, 8, 46]). Simi-
larly, reference to a paper in nursing (ref. [15]) is probably
not the best choice.
Authors’ response: We have added more suitable sources.
3. Some references are not quoted sequentially. For ex-
ample, ref. [41] on p. 7 is missed as are refs [59] and
[60] on p. 23. Also, ref. [71] does not seem to appear
anywhere in the text.
Authors’ response: We have corrected the references.
4. The paper contains several repetitions as well as
lengthy and unnecessary discussions. The results section
can be compressed. Also, the number of tables and fig-
ures is too large. Some tables can be combined and
some omitted because they duplicate results presented
graphically.
Authors’ response: Repetitions have been removed and
multiple discussions have been shortened. We have
merged Tables 1, 2 and 7 into one table. However, we
fear that by trying to further condense these items and
the Results section important information might be ren-
dered relatively unclear.
5. P. 38. An advertisement of the activities of the authors’
workplace should not be a part of scientific paper.Authors’ response: Having taken into account this
comment we have rephrased the paragraph under con-
sideration as follows: “Our ultimate goal is to simulate
the spatiotemporal response of clinical tumours to vari-
ous treatment schemes and schedules in the patient indi-
vidualized context. This extremely challenging task
entails the exploitation of multiscale clinical data, for
the purpose of conducting thorough fitting and valid-
ation studies of the model and obtaining parameter es-
timates representative of the human patient. An
invaluable help toward obtaining patient-specific pre-
dictions is expected to be provided by the identification
of potential biomarkers of bevacizumab response, emer-
ging from numerous clinical trials. It should be noted
that the work presented is also positioned within the
large scale integrated project CHIC [Computational
Horizons In Cancer (CHIC): Developing Meta- and
Hyper-Multiscale Models and Repositories for In Silico
Oncology (FP7-ICT-2011-600841). The latter aims at
developing cutting edge ICT tools, services and secure
infrastructure to foster the development of elaborate
and reusable integrative models (hypermodels) and lar-
ger repositories so as to demonstrate benefits of having
both the multiscale data and the corresponding models
readily available. In this context, the presented model
constitutes one of the component models of the CHIC
model repository, with the ultimate goal of being com-
bined with other CHIC models to form clinically-
relevant hypermodels.” Please note that no working
affiliations appear in this updated version of the
paragraph.
6. Ref. [4] does not include page numbers.
Authors’ response: This has been addressed.
7. Check the title of ref. [6].
Authors’ response: This was corrected.
Quality of written English: Not suitable for publication
unless extensively edited.Final comments
Reviewer Recommendation Term: Endorse publication
Quality of written English: Acceptable
Reviewer summary: In response to my comments the
authors included additional explanations and caveats
into the paper making it clear that several aspects of
their work are preliminary. The style of the paper has
improved. There are still a few minor stylistic imperfec-
tions present; hope they can be addressed by the journal’s
technical editor. My final minor technical comments are
given in the Comments to Authors.
Reviewer recommendations to authors: The new
revision represents an improvement both in terms of
substance and style. I think that another round of revision
is unnecessary.
Argyri et al. Biology Direct  (2016) 11:12 Page 29 of 31Reviewer's report 2: Prof Tomas Radivoyevitch, Case
Western Reserve University, USA.
Relative to the landmark work of Hahnfeldt et al. [28]
on which this work is based, moving toward least squares
estimates of parameters is a step in the right direction as it
yields 95 % confidence intervals (CI) of the parameter
estimates.
Least squares estimation is done here for 4 parameters,
but CI were not provided. Presumably CI were not shown
because some had upper limits of infinity, but knowing
which parameters could not be identified, and for those
that could, the extent to which they could (based on how
large the upper limits are), would have been informative.
In the third paragraph prior to Conclusions it is men-
tioned that different initial conditions for the optimization
lead to different answers. I see this as indicating over-
parameterization that cannot be overcome by starting in
different negative log-likelihood valleys. The model should
be parsimonious enough for fitting to be fairly robust to
fairly reasonable initial parameter values. If this were
achieved, initial values would not be an explanation of
poor fit. I also would not blame PlotDigitizer. Sloppy
experiments and the model missing a concept/other
parameters are two other possibilities, but the model is
already over-parameterized, so perhaps living with
some correlated residuals is OK for now. Recent papers
on identifiability of biomathematical ODEs include:
1. Raue, A., Kreutz, C., Theis, F.J. & Timmer, J. Joining
forces of Bayesian and frequentist methodology: a study
for inference in the presence of non-identifiability. Philo-
sophical transactions. Series A, Mathematical, physical,
and engineering sciences 371, 20110544 (2013).
2. Kreutz, C., Raue, A. & Timmer, J. Likelihood based
observability analysis and confidence intervals for pre-
dictions of dynamic models. BMC Systems Biology 6,
120 (2012).
3. Raue, A., Becker, V., Klingmuller, U. & Timmer, J.
Identifiability and observability analysis for experimental
design in nonlinear dynamical models. Chaos 20, 045105
(2010).
4. Raue, A. et al. Structural and practical identifiability
analysis of partially observed dynamical models by exploit-
ing the profile likelihood. Bioinformatics 25, 1923–9
(2009). Implementation. Simulations in R with ODEs in C
are fast enough to be nested in likelihood calculations.
The model of Hahnfeldt et al. is available in such C code
in the files philMod.c and philModAE.c in http://epbi-
radivot.cwru.edu/EPBI473/files/wk13tumorTherapy. Also
available in this folder are scripts that use this code to pro-
duce maximum likelihood estimates (including 95 % CI
from Hessians); these scripts were written in 2005 (for the
R package odesolve) and could be streamlined today using
the R packages bbmle (for CI and profiles) and deSolve
(which adds conveniences that extend odesolve).Authors’ response: We thank Prof Radivoyevitch for his
remarks and suggestions on our work.
The sentence “In particular, local solvers such as
lsqnonlin provide the user with a local minimum de-
pending on the selected starting point, but not necessarily
the best or global minimum.” was meant to explain the
way that a local solver works. What we simply intended
to state was that having in most cases searched through
a very specific “neighbourhood” of the parameter space
(we perturbed the parameters to be estimated around
reference values) and given the locality of the fitting
method used, we cannot be sure that there is not a better
solution somewhere else in the parameter space.
Of course, we agree with Prof Radivoyevitch that iden-
tifiability analysis is a valuable tool to evaluating the pre-
dictive power of the model since the outcome of the model
prediction is dependent on the identifiability of the param-
eters involved. However, in our case, identifiability analysis
was considered premature, in the sense that the exact
boundaries of the multidimensional parameter subspace
yielding biologically acceptable tumour volume behaviour
have not been yet determined. Hence, even if the system
proved to be nonidentifiable it could still be valid, as in
real-life applications, such as the one studied in this paper,
what we actually seek for is not a solution unique for the
parameter space in its entirety, but a solution unique in a
specific parameter subspace that includes valid parameter
values for e.g. a human cancer patient.
A paragraph has been added, stating the possibility of
over-parameterization of the model, explaining the sig-
nificance of identifiability analysis and also our ration-
ale. See page 34 “However, potential non-uniqueness of a
solution… human cancer patient.”
Reviewer's report 3: Dr Lutz Edler, German Cancer
Research Center, Germany
The authors have addressed all my comments in the
reply letter and implemented changes in response to a
larger part of the many comments, accounting also the
limitations set by the journal (e.g. not having figures and
tables near the text they belong to), This correspondence
together with the substantially revised text should suffice
the paper now for the benefit of the engaged reader en-
thusiastic for modeling carcinogenesis, even if I liked to
see methods and results better seperated.
In conclusion the paper is ready for publication from
this perspective. If the authors have the option to polish
English language and to some extent alos grammar, they
should do so. However, I also see the trade off between
such editing and the delay of publication. Therefore "ac-
ceptable" is indicated.
Quality of written English: Acceptable
Authors’ response: We thank Dr Edler for his remarks.
We have further improved the language of the manuscript.
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